

Références

Références générales

- Agence de Santé publique du Canada. Conseils de santé et rapports internationaux. http://www.phac-aspc.qc.ca/tmp-pmv/pub_f.html [1]
- Comité consultatif national de l'immunisation (CCNI). Guide canadien d'immunisation, 6e éd. Ottawa, Association médicale du Canada (AMC), 2002.
- CDC (Centers for Diseases Control and Prevention). Health information for international travel 2005-2006. Atlanta: US Department of Health and Human Services, Public Health Service, 2005.
- CDC. Travel Information. <http://www.cdc.gov/travel/index.htm> [2] .
- CIA. World Factbook. <http://www.odci.gov/cia/publications/factbook/index.html> [3].
- Cook CC et Zumla A, Manson's tropical diseases, 21e ed. Philadelphie: WB Saunders; 2003.
- Dupont HL, Stephen R. Textbook of travel medicine and health. Hamilton, B. C. Decker, 2001.
- International Association for Medical Assistance to Travellers (IAMAT). <http://www.iamat.org> [4]
- Keystone JS, Kozarsky PE, Freedman, DO, Nothdurft HD, Connor BA. Travel medicine. Edinburgh, Mosby, 2004.
- Mandell GL et al. Principles and practice of infectious diseases, 6e éd. New York: Churchill Livingstone, 2005.
- Microsoft. Atlas mondial Encarta, Microsoft, 1997.
- Ministère des Affaires étrangères et du Commerce international (MAECI), Canada. Informations sur les pays. <http://www.dfait-maeci.gc.ca/geo/menu-f.asp> [5]
- Organisation mondiale de la santé (OMS). Voyages internationaux et santé - Vaccination exigée et conseils d'hygiène 2004. Genève, OMS, 2004. <http://www.who.int/fr/index.html> [6] .
- Pan American Health Organization (PAHO). Health in the Americas - Volume II : Country Health Profiles. Washington, PAHO, 1998. <http://www.paho.org/english/country.htm> [7] .
- Provost S., Gagnon S., Lonergan G., Bui YG, Labbe AC. Hepatitis A, typhoid and malaria among travelers-surveillance data from Quebec (Canada). J Travel Med. 2006 Jul-Aug; 13(4) : 219-26.
- Rose, ST. International travel health guide, 9e éd. Northampton, MA, Travel Medicine, 1998.
- Recommandations générales aux voyageurs.mai 2005. http://www.phac-aspc.qc.ca/tmp-pmv/236_f.html [8] .
- Strickland GT, dir. de la réd. Hunter's tropical medicine and emerging infectious diseases, 8e ed.

Philadelphie : WB Saunders; 2000.

- U.S. State Department - Consular Affairs. <http://travel.state.gov/travel/tips/health/health-1185.html> [9].
- World Bank Group. Countries and regions. <http://www.worldbank.org/html/extdr/regions.htm> [10] (2001).

Altitude et acclimation

- Andrew M. et al. Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness. In: Wilderness and Environmental Medicine, 21, 146-155 (2010).
- Bansch P, Maggiorini M, Ritler M, Noti C, Vock P, Oelz O. Prevention of high altitude pulmonary edema by nifedipine. NEJM 1991; 325 : 1284-9.
- Bates MG. et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension double blind, randomized, placebo-controlled trial. In: High Alt Med Biol. 2011 Fall; 12 (3): 207-14.
- Bezruchka S. High altitude medicine. The medical clinics of North America 1992; 76 : 1481-1498.
- Bezruchka S. Mountaineering activities and high altitude associated disorders. Travel Medicine Advisor : 20.1-20.14.
- Boussou P. Performance et entraînement en altitude, Aspect physiologique et physiopathologique. Décarie, 1987.
- Centers for Disease Control and Prevention. CDC Health Information for International Travel 2012. New York: Oxford University Press:2012. Chapter 2: Altitude Illness.
- Comité consultatif de la médecine tropicale et de la médecine des voyages. Déclaration sur les maladies de haute altitude. Relevé des maladies transmissibles au Canada. Volume 33, DCC 5, 1er avril 2007.
- Eliswoth AJ, Meyer EF, Larson EB. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med 1991; 154 : 289-293.
- Hackett P H et Roach R C. High altitude illness. N Engl J Med 2001, 12 juillet : 345-2 : 107-114.
- Hullgreen H. High altitude medical problems. Scientific American 1990 : 1-13.
- Hultgren HN. Effects of altitude upon cardiovascular diseases. J Wilderness Med 1992; 3 : 301-308.
- Kayser B. Acute mountain sickness in western tourists around the Thorong pass (5400 m) in Nepal. J Wilderness Med 1991; 2 : 110-117,140-149.
- Keystone J S et al. Travel Medicine. Mosby, St-Louis, MO, 2004. p. 363-375.
- Keystone J S et al. Travel Medicine. Mosby, St-Louis, MO, 2008.
- Leibson C, Brown M, Thiboteau S, Stevenson D, Vreman H, Cohen Ret al. Neonatal hyperbilirubinemia at high altitude. AJDC 1989; 143 : 983-987.
- MC Intosh Iain B. High altitude, high risk travel. Travel Medicine International 1989 : 164-167.
- Montgomery AB, Mills J, Luce JM. Incidence of acute mountain sickness at intermediate altitude. JAMA 1989; 261 : 732-734.

- Moore LG. Altitude - aggravated illness : Examples from pregnancy and prenatal life. Ann Emerg Med 1987; 16 : 965-973.
- Oelz O, Maggiorini M, Ritler M, Waber V, Jenni R, Vock Pet al. Nifedipine for high altitude pulmonary edema. Lancet nov. 1989; 25 : 1241-1244.
- Pollard Andrew J, et al. Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001. High Altitude Medicine and Biology. 2001; vol 2 no 3 : 389-403.
- Rabold M. High-altitude pulmonary edema : a collective review. Am J Emerg Med 1989; 7 : 426-33.
- Rabold MB. Dexamethasone for prophylaxis and treatment of acute mountain sickness. J Wilderness Med 1992; 3 : 54-60.
- Robertson JA et Shlim DR. Treatment of moderate acute mountain sickness with pressurization in a portable hyperbaric (Gamow) Bag. J Wilderness Med 1991; 2 : 268-273.
- Ruchalet JP et Rathat C. Pathologie et altitude. Paris, Masson, 1991.
- Sutlon JR. Mountain sickness. Neurologic clinics 1992; 10 : 1015-1030.
- Swapnil J. Paralakar et Jagdish H. Paralakar. High Altitude Medicine. In: Indian Journal of Occupational and Environmental Medicine. Jan-Apr; 14 (1): 6-12. 2010.
- Tyukodi. Anton high altitude illness. Emergency Prehospital Medicine, février 1988; 2(4).
- UIAA. Official standards of the UIAA medical commission. Trekking and expedition medicine. Emergency treatment of acute mountain sickness and high altitude pulmonary oedema. 1993.
- Ward. Milledge et West. High altitude medicine and physiology. Philadelphie, University of Pennsylvania, 1989.
- West JB. Acclimatization and tolerance to extreme altitude. J Wilderness. Med 1993; 4 : 17-26.
- West JB. Limiting factors for exercise at extreme altitudes. Clinical physiology 1990; 10 : 265-272.
- Wilkerson James DA. Medicine for mountaineering, 3e éd. 1985.
- Zell SC et Goodman PH. Acetazolamide and dexamethasone in the prevention of acute mountain sickness. West J Med 1988; 148 : 541-545.

Arthropodes

- RMTC-ASP, Déclaration relative aux mesures de protection individuelle pour prévenir les piqûres ou morsures d'arthropodes. VOLUME 38. DCC3. Novembre 2012.
- STEFEN R., DUPONT H., WILDER-SMITH A. Manual of travel medicine, BC Decker Inc ed. 2013.
- TURGEON J., HERVOUET-ZEIBER C., OVETCHKINE P., BERNARD-BONIN A-C., GAUTHIER M., WEBER, Dictionnaire de pédiatrie, 3e édition. TC Média Livres Inc 2015.

Chikungunya

- Ministère de la Santé et des services Sociaux. Bulletin Flash Vigie. Vol 9, no 8 , octobre 2014
- Morrison TE. Reemergence of Chikungunya virus. Journal of Virology 2014; (88) 11644-47
- Pan-American Health Organization (PAHO). Number of cumulative cases 2015 (www.paho.org [11])
- Weaver SD, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. The New England Journal of Medicine 2015; (372) 1231-9

- Zeana, C, Kelly P et al. Post-Chikungunya rheumatic disorders in travelers after return from the Caribbean. *Travel medicine and Infectious Diseases* 2016; (14) 21-5

Choléra

- Berger S, Shapiro I. Re-emergence of cholera vaccine. *J Travel Med* 1997; 4 : 58-60.
- Cholera working group of Bangladesh. Large epidemic of cholera-like disease in Bangladesh caused by *Vibrio cholerae* O139 synonym Bengal. *Lancet* 1993; 342 : 387-390.
- Cryz SJ Jr et al. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain, CVD 103-HgR in Swiss adults. *Vaccine* 1990; 8 : 577-580.
- Dupont HL, Steffen R. Gastrointestinal infections in travellers. *Cholera* 2 : 1-27.
- Infectious disease surveillance center of Japan. Cholera in Japan as of August 2002. *IASR* 2002; 23 : 219-220. <http://idsc.nih.go.jp/iasr/iasr-ge1.html> [12].
- Kollaritsch H et al. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. *J Inf Dis* 1997; 175 : 871-5.
- Kotloff KL. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR : Results of a randomized, placebocontrolled, double-blind crossover trial. *Infection and Immunity* 1992; 4430-4432.
- Levine MM, Kaper JB. Live oral vaccines against cholera : an update. *Vaccine* 1993; 11 (2) : 207-212.
- Levine MM, Kaper JB. Live oral cholera vaccine : from principle to product. *Bulletin Institut Pasteur/Elsevier* 1995; 93 : 243-253.
- OMS. Global Alert and Response (GAR). <http://www.who.int/csr/don/archive/disease/cholera/en> [13]
- OMS, Voyage internationaux et santé 2012 (mise à jour 2014). <http://www.who.int/ith/en/> [14]
- OMS, Statistiques sanitaires mondiales 2012 et 2011 <http://www.who.int/gho> [15]
- PAHO cholera health topic <http://www.paho.org/cholera> [16]
- PAHO/WHO Epidemiological Alerts and Updates http://www.paho.org/hq/index.php?option=com_topics&view=article&id=13&Itemid=40745&lang=en [17]
- Pastor, M. Predraz, J.L., Esquisabel, A. The state-of-the-art of approved and under-development cholera vaccines, *Vaccine* 2013; 31 (38) : 4069-4078.
- RMTc-Déclaration sur le nouveau vaccin oral contre le choléra et la diarrhée du voyageur. Volume 31 • DCC-7. <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc> [18]
- Sack DA, Bradley Sack R, Balakrish Nair G, Siddique AK, Cholera. *Lancet* 2004; 363 : 223-233.
- Simajuntak CH et al. Safety, immunogenicity, and transmissibility of singledose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. *J Inf Dis* 1993; 168 : 1169-76.
- Tacket CO et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. *J Inf Dis* 1992; 166 : 83-41.
- Trach DD. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. *Lancet* January 25, 1997; 349 : 231-235.
- Weekly Epidemiological Record (WER), Vaccins anticholériques: note d'information de l'OMS
WER, Cholera 2015, Vol. 91, No. 38, p. 433-440, September 2016
WER, Cholera 2014, Vol. 90, No. 40, p. 517-544, October 2015
WER, Cholera 2013, Vol. 89, No. 31, p. 345-356, August 2014

WER, Cholera 2012, Vol. 88, No. 31, p. 321–336, August 2013
WER, Cholera 2011, Vol. 87, No. 31-32, p. 289–304, August 2012
WER, Cholera vaccines: WHO proposition paper, Vol 85, No 13, p. 117-128, March 2010,
<http://www.who.int/wer> [19]

Dengue

- CDC. Imported dengue–United States, 1996. *MMWR* 1998 Jul 10; 47(26) : 544-547.
- CDC. Potential risk for dengue hemorrhagic fever : The isolation of serotype dengue-3 in Mexico. *Emerging Infectious Diseases* April-June 1996; 2(2).
- Cire Océan indien. Le point épidémio 2010 : no 46.
- Direction générale de la protection de la santé – Laboratoire de lutte contre la maladie. Rapports internationaux sur l’activité de la fièvre dengue et de la dengue hémorragique. 26 juin 1998.
- Duperval R, Frost EH, Artsob H. Dengue fever with hemorrhagic manifestations in travellers returning to Québec from Asia. *Can J Infect Dis* 1993;4 : 220-222.
- Fauran P. New epidemiological aspects of dengue. *Bull Soc Pathol Exot* 1996; 89(2) : 163-4.
- Fauran P. Prediction and prevention of dengue epidemics. *Bull Soc Pathol Exot* 1996; 89(2) : 123-6.
- Franco L, Di Caro A, Carletti F et al. Recent expansion of dengue virus serotype 3 in West Africa. *Eurosurveillance* 2010; 15 (7)
- Freedman DO, Weld LH, Kozarsky PE et al. Spectrum of disease and relation to place of exposure among ill returned travellers. *New England Journal of Medicine* 2006 Jan 12; 354 (2) : 119-130.
- Gjenero-Margan I, Aleraj B, Krajcar D et al. Autochthonous dengue fever in Croatia, August-September 2010. *Eurosurveillance* 2011; 16 (9) 1-4.
- Gubler DJ, Clark GG. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. *Emerg Infect Dis* 1995 Apr-Jun; 1(2) : 55-7.
- Gubler DJ. Dengue and dengue hemorrhagic fever. *Clin Microbiol Rev* 1998 Jul; 11(3) : 480-96.
- Gubler DJ, Kuno G. Dengue fever & dengue hemorrhagic fever. Wallingford (UK), CAB Intl, 1998.
- Halstead SB, Udomsakdi S, Singharaj P et al. Dengue and chikungunya virus infection in man in Thailand, 1962-64III : clinical, epidemiologic, and virologic observations on disease in non-indigenous white persons. *Am J Trop Med Hyg* 1969;18 : 984-996.
- Janisch T, Preiser W, Berger A, Niedrig M, Mikulicz U, Thoma B, Doerr HW. Emerging viral pathogens in long-term expatriate(II) : Dengue virus. *Trop Med Int Health* 1997 Oct; 2(10) : 934-40.
- Jelinek T. Dengue fever in international travelers. *Clin Infect Dis* 2000; 31 : 144-147.
- Jelinek T, Dobler G, Holscher M, Loscher T, Nothdurft HD. Prevalence of infection with dengue virus among international travelers. *Arch Intern Med* 1997 Nov 10; 157(20) : 2367-70.
- Jelinek T, Muhlberger N, Harms G et al. Epidemiology and clinical features of imported dengue fever in Europe: Sentinel surveillance data from TropNetEurop. *Clin Infect Dis* 2002; 35 : 1047-1052.
- Jetten TH, Focks DA. Potential changes in the distribution of dengue transmission under climate warming. *Am J Trop Med Hyg* 1997 Sep; 57(3) : 285-97.
- Karp BE. Dengue fever: a risk to travelers. *Md Med J* 1997 Jul; 46(6) : 299-302.
- Lancet. Editorial Dengue in the Americas–time to talk. *Lancet* 1997 Aug 16; 350(9076) : 455.
- Lange WR, Beall B, Denney SC. Dengue fever: a resurgent risk for the international traveler. *Am Fam Physician* 1992;45 : 1161-1168.
- La Ruche G, Souarès Y, Armengaud A et al. First two autochthonous dengue virus infections in metropolitan France, September 2010. *Eurosurveillance* 2010; 15 (39) 1-5.
- Lindbäck H, Lindbäck J, Tegnell A et al. Dengue fever in travelers to the tropics, 1998 and 1999. *Emerg Infect Dis* 2003;9 : 438-442.

- McBride WJ, Mullner H, LaBrooy JT, Wronski I. The 1993 dengue-2 epidemic in Charters Towers, North Queensland : clinical features and public health impact. *Epidemiol Infect* 1998 Aug; 121(1) : 151-6.
- Mondet B, da Rosa AP, Vasconcelos PF. The risk of urban yellow fever outbreaks in Brazil by dengue vectors. *Aedes aegypti* and *Aedes albopictus*. *Bull Soc Pathol Exot* 1996; 89(2) : 107-13.
- OMS. Dengue haemorrhagic fever: Diagnosis, treatment, prevention and control. Genève, OMS, 1997.
- Ostroff SM, Kozarsky P. Emerging infectious diseases and travel medicine. *Infect Dis Clin North Am* 1998 Mar; 12(1) : 231-41.
- PAHO. Dengue and dengue hemorrhagic fever, 1996. *Epidemiol Bull* 1996 Dec; 17(4) : 12-4.
- PAHO/WHO Communicable diseases program. Population at risk and incidence of dengue and dengue hemorrhagic fever (DHF) in the Americas - 1995. PAHO.
- Phoutrides EK, Coulibaly MB, George CM et al. Dengue virus seroprevalence among febrile patients in Bamako, Mali : results of a 2006 surveillance study. *Vector borne zoonotic diseases* 2011; 11 (11) 1479-85.
- Pinheiro FP, Corber SJ. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. *World Health Stat Q* 1997; 50 (3-4) : 161-9.
- Reynes JM. Dengue in French Guiana. History and present status. *Bull Soc Pathol Exot* 1996; 89(2) : 98-100.
- Rigau-Pérez JG, Clark GG, Gubler DJ et al. Dengue and dengue haemorrhagic fever. *Lancet* 1998;352 : 971-977.
- Rigau-Perez JG, Gubler DJ, Vorndam AV, Clark GG. Dengue: A literature review and case study of travelers from the United States, 1986-1994. *Travel Med* 1997 Jun 1; 4(2) : 65-71.
- Rodhain F. The situation of dengue in the world. *Bull Soc Pathol Exot* 1996; 89 (2) : 87-90.
- Rosen L. Dengue hemorrhagic fever. *Bull Soc Pathol Exot* 1996; 89 (2) : 91-3.
- Rossi CA, Drabick JJ, Gambel JM, Sun W, Lewis TE, Henchal EA. Laboratory diagnosis of acute dengue fever during the United Nations mission in Haiti, 1995-1996. *Am J Trop Med Hyg* 1998 Aug; 59(2) : 275-8.
- Santé Canada. Recommandation relative aux voyages : Dengue et voyages internationaux. *RCMT* 1996; 22 : 25-28.
- Savage HM, Fritz CL, Rutstein D, Yolwa A, Vorndam V, Gubler DJ. Epidemic of dengue-4 virus in Yap State, Federated States of Micronesia, and implication of *Aedes hensilli* as an epidemic vector. *Am J Trop Med Hyg* 1998 Apr; 58(4) : 519-24.
- Sharp TW, Wallace MR, Hayes CG et al. Dengue fever in U.S. troops during Operation Restore Hope, Somalia, 1992-1993. *Am J Trop Med Hyg* 1995;53 :89-94.
- Shirtcliffe P, Cameron E, Nicholson KG, Wiselka MJ. Don't forget dengue! Clinical features of dengue fever in returning travellers. *J R Coll Physicians Lond* 1998 May-Jun; 32(3) : 235-7.
- Tolou H, Baudon D, Laroche R. Current status of dengue virus infections. Epidemiologic and pathogenetic aspects. *Med Trop (Mars)* 1997; 57(1) : 71-6.
- Tolou H, Durand JP, Pisano MR. Current status of dengue, *Med Trop (Mars)* 1997; 57(3 Suppl) : 70-3.
- Trofa AF, DeFraités RF, Smoak BL, Kanesa-thasan N, King AD, Burrous JM, MacArthy PO, Rossi C, Hoke CH Jr. Dengue fever in US military personnel in Haiti. *JAMA* 1997 May 21; 277(19) : 1546-8.
- Von Zielonka M. Risques infectieux et voyages. Pradel, Paris, 1992.
- Wichmann O, Gascon J, Schunk M et al. Severe dengue virus infection in travellers: risk factors and laboratory indicators. *Journal of Infectious Diseases* 2007 Apr 15; 195 : 1089-96.
- Yebakima A. Control of *Aedes aegypti* in Martinique. Contribution of entomology studies. *Bull Soc Pathol Exot* 1996; 89(2) : 161-2.

Diarrhée des voyageurs

Références pour la mise à jour de février 2017 :

- Augé C, Karam J, Turgeon J. *L'allongement du QT: devrait-on s'inquiéter?* Québec Pharmacie, septembre 2014. www.professionsanté.ca [20]
- Cummings J, Christie S, Cole T. *A study of fructo oligosaccharides in the prevention of travellers' diarrhoea.* Aliment Pharmacol Ther. 2001;15(8):1139-45.
- Daneman N, Lu H, Redelmeier DA. *Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study.* BMJ Open. 2015;5(11):e010077.
- Emerging Infectious Diseases. *Quinolone Safety and efficacy.* www.cdc.gov/eid [21]. Vol 11, No 6, June 2005
- FDA U.S. Food and Drug Administration. Drug Safety Communications. <http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm> [22]
- FDA U.S. Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients, <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics> [23]
- FDA Updates warnings for fluoroquinolone antibiotics. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm> [24]
- FDA For immediate release, July 2016.
- Gouvernement du Canada. Résumé de l'examen de l'innocuité - fluoroquinolones systémiques (ciprofloxacine, lévofloxacine, moxifloxacine et norfloxacine) - Santé Canada, <https://hpr-rps.hres.ca/reg-content/resume-examen-innocuite-detail.php?lang=fr&linkID=SR00226#footnotes> [25]
- Lee C, Gabriel Lee M, Chen Y, Lee S, Chen Y, Chen S, et al. *Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone.* JAMA Intern Med. 2015;175(11):1839-47.
- Lee C, Lee M-G, Hsieh R, Porta L, Lee W, Lee S, et al. *Oral Fluoroquinolone and the Risk of Aortic Dissection.* J Am Coll Cardiol. 2018;72(12):1369-78.
- Pasternak B, Inghammar M, Svanström H. *Fluoroquinolone use and risk of aortic aneurysm and dissection: Nationwide cohort study.* BMJ. 2018;360:k678
- Santé Canada, MedEffet <http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/fluoroquinolones2-fra.php> [26]

- Up to date. Special Alerts. Fluroquinolone Antibacterial Drugs safety Alert July 2016
- Virk A, Mandrekar J, Berbari EF, Boyce TG, Fischer PR, Kasten MJ, *et al.* A randomized, double blind, placebo-controlled trial of an oral synbiotic (AKSB) for prevention of travelers' diarrhea. *Journal of Travel Medicine.* 2013; 20(2):88-94

Références des éditions antérieures :

- Adachi JA *et al.* Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. *CID* 2003; 37 : 1165-71.
- Adachi JA *et al.* Enteroaggregative *Escherichia coli* as a major etiologic agent in traveler's diarrhea in 3 regions of the world. *Clin Infect Dis* 2001; 32 : 1706-1709.
- Bierer DW. Bismuth subsalicylate : history, chemistry, and safety. *Rev Infect Dis.* 1990;12 Suppl 1 : S3-8.
- BRIGGS, Gerald G.; FREEMAN, Roger K, *Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk* », 10th edition, 2015
- Centers for Disease Control and Prevention. Managing acute gastroenteritis among children : oral rehydration, maintenance, and nutritional therapy. *MMWR* 2003; 52(No. RR-16) : 1-16.
- CDC Yellow book, 2014
- Cheng AC *et Thielman NM.* Update on traveler's diarrhea. *Curr Infect Dis Rep* 2002; 4 : 70-77.
- Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV). Déclaration sur la diarrhée du voyageur. *Relevé des maladies transmissibles au Canada.* Vol 27 DCC-3. 15 mars 2001.
- CONNOR, BA. [27]« Traveler's diarrhea. The Yellow Book » [27][en ligne], Centers for Disease Control Health Information for International Travel.
- Déclaration sur la diarrhée du voyageur. Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV). Agence de la santé publique du Canada. Avril 2015
- Déclaration sur le nouveau vaccin oral contre le choléra et la diarrhée du voyageur. Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV) et Comité consultatif national de l'immunisation (CCNI). *RMTC.* Volume 31. DCC-7. 1 juillet 2005
<http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/05vol31/asc-dcc-7/index-fra.php> [28]
- Ericsson CD *et Johnson PC.* Safety and efficacy of loperamide. *Am J Med* 1990; 88 : 10S-14S.
- Ericsson CD. Nonantimicrobial agents in the prevention and treatment of traveler's diarrhea. *Clin Infect Dis* 2005; 41 Suppl 8 : S557-563.
- GINEFRI, Lauriane *et Ema FERREIRA.* « La diarrhée », [auteure du livre] E. Ferreira, B. Martin *et C. Morin.* *Grossesse et allaitement Guide thérapeutique,* Montréal : CHU Sainte-Justine, 2e édition, 2013, chapitre 19, pp. 438-447.
- GINEFRI, Lauriane *et Caroline MORIN.* « Anti-infectieux durant l'allaitement », [auteure du livre] E. Ferreira, B. Martin *et C. Morin.* *Grossesse et allaitement Guide thérapeutique,* Montréal : CHU Sainte-Justine, 2e édition, 2013, chapitre 29, pp. 641-671.

- Gouvernement du Canada, Solutions de réhydratation orale, <http://www.voyage.gc.ca/voyager/sante-securite/rehydratation> [29]
- Hill DR. Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries. *Am J Trop Med Hyg* 2000; 62 : 585-589.
- Hill, David et collab. Oral cholera vaccines: use in clinical practice. <http://infection.thelancet.com> [30] Vol 6 June 2006
- KOO Hoonmo. DUPONT Herbert et HUANG David. Therapeutics and Clinical Risk Management. The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea. Dovepress. October 2009
- Lexicomp Clinical Drug Information 2016 : en ligne <http://www.wolterskluwer CDI.com/lexicomp-online/> [31]
- Loscher T et Connor BA. Clinical presentation and treatment of travelers' diarrhea. In : Keystone JS et al. dir. de la réd. *Travel medicine*. St Louis Mo, Mosby, 2004, 175-199.
- Ministère de la Santé et des Services sociaux, *Protocole d'immunisation du Québec Section 10.6.1 Chol-Ecol-O : vaccin oral contre le choléra et la diarrhée à ETEC*, <http://publications.msss.gouv.qc.ca/msss/fichiers/piq/chap10-6-1.pdf> [32]
- Peltola H et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. *Lancet* 1991; 338 : 1285-1289.
- Rashed Selim et collab. *Médecine tropicale, santé internationale et santé de l'enfant immigrant..* Éditions santé internationale. 2007
- Rendi-Wagner P and Kollaritsch H. Drug prophylaxis for travelers' diarrhea. *CID* 2002; 34 : 628-33.
- Résumé de la Déclaration sur la diarrhée du voyageur. Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV). Agence de la santé publique du Canada. Novembre 2015
- Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. *PLoS ONE*. 2012;7(4).
- RMTC-Déclaration du CCMTMV sur la diarrhée du voyageur Vol. 27 (ACS-3)/(DCC-3) 15 mars 2001 <http://www.collectionscanada.gc.ca/webarchives/20071124190633/http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/01pdf/acs27-3.pdf> [33]
- Robins-Browne RM and Hartland EL. *Escherichia coli* as a cause of diarrhea. *J Gastroenterol Hepatol* 2002; 17 : 467-75.
- Sanford guide to antimicrobial therapy 2016, 46th edition : <http://webedition.sanfordguide.com/> [34]
- Shah, Nipam et autres. Global Etiology of Travellers' Diarrhea : Systematic Review from 1973 to the Present. *Am. J. Trop. Med. Hyg* 80(4), 2009, pp 609-614
- Steffen R et al. Epidemiology, etiology and impact of traveler's diarrhea in Jamaica. *JAMA* 1999; 281 : 811-817.
- Steffen R. Epidemiology of traveler's diarrhea. *Clin Infect Dis* 2005; 41 Suppl 8 : S536-540.
- Sullivan Å, Nord CE. Probiotics and gastrointestinal diseases. *J Intern Med*. 2005;257(1):78-92.
- The medical letter. Volume 46 (Issue 1191) September 13, 2004. Rifaximin (Xifaxan) for travellers.
- Thielman NM et Guerrant RL. Acute infectious diarrhea. *NEJM* 2004; 350 : 38-47.
- Vargas M et al. Prevalence of diarrheagenic *Escherichia coli* strains detected by PCR in patients with travelers' diarrhea. *Clin Microbiol Infect* 1998; 4 : 682- 688.

Eau et Aliments

- Backer H. Field water disinfection. Dans : Averbach P. ed. Wilderness medicine, 4e edition, St-Louis, MO : 2001 : 1186-1236.
- Backer H, Hollowell J. Use of iodine for water disinfection : Iodine toxicity and maximum recommended dose. Environ Health Perspect 2000; 108 : 679-684.
- Backer H. Water disinfection for International Travelers. Dans : Keystone J. Travel Medicine, 1ère edition. Mosby, St-Louis, MO, 2004 : 49-59.
- Bandres J, Mathewson J., DuPont H. Heat susceptibility of bacterial enteropathogens. Arch Intern Med 1988; 148 : 2261-2263.
- Gerba C, Naranjo J. Microbiological water purification without the use of chemical disinfection. Wilderness Environ Med 1999; 10 : 12-16.
- US environmental Protection Agency. Guide standard and protocol for testing microbiological water purifiers. Report to Task Force. Cincinnati : US environmental Protection Agency; 1987.

Encéphalite européenne à tiques

- Amicizia D, Domnich A, Panatto D et al. Epidemiology of TBE in Europe and its prevention by available vaccines. Human Vaccines and Immunotherapeutics 2013, vol 9, no 5, 1163-71.
- Comité consultatif de la médecine tropicale et de la médecine des voyages. Déclaration sur l'encéphalite à tiques. Relevé des maladies transmissibles au Canada 2006; 32p.
- Donoso Mantke O, Schädler R, Niedrig M. A survey on cases of tick-borne encephalitis in European countries. Eurosurveillance 2008, Volume 13, no 17.
- Donoso Mantke O, Escadafal C et al. Tick-borne encephalitis in Europe, 2007 to 2009. Eurosurveillance 2011, vol 16, no 39.
- Elyan DS, Moustafa L et al. Serological evidence of Flaviviruses infection among acute febrile illness patients in Afghanistan. The Journal of Infection in Developing Countries 2014, vol 8, no 9 , 1176-80.
- Erganay K, Saygan MB et al. Confirmed exposure to TBE virus and probable human cases of tick-borne encephalitis in Central/ Northern Anatolia, Turkey. Zoonoses Public Health 2011, vol 58, no 3, 220-7.
- European Centre for Disease Prevention and Control. Epidemiological situation of tick-borne encephalitis in the European Union and European free Trade Association countries, ECDC 2012.
- Fomsgaard A, Christiansen CB, Bodker R. First identification of TBE in Denmark outside of Bornholm, August 2009. Eurosurveillance 2009, vol 14, no 36.
- MMWR. Tick-borne encephalitis among US travelers to Europe and Asia- 2000-2009. Weekly report 2010, vol 59, no 11.
- Mohareb E, Christova I et al. Tick-borne encephalitis in Bulgaria, 2009 to 2012. Eurosurveillance

2013, vol 18, no 46.

- Plotkin S, Orenstein WA, Offit P, Vaccines, 5e ed. Philadelphia, Saunders-Elsevier, 2008.
- Schuler M, Zimmermann H et al. Epidemiology of TBE in Switzerland, 2005 to 2011. *Eurosurveillance* 2014, vol 19, no 13.
- Steffens I et al. FSME. *Epidemiologisches Bulletin* (Robert Koch Institut) avril 2005; 16.
- Strauss R et al. Tickborne encephalitis in Europe : basic information, country by country. *Eurosurveillance Weekly* 2004, vol 8, no 29.
- Süss J. Epidemiology and ecology of TBE relevant to the production of effective vaccines. *Vaccine* 2003; 21 : S1/19-S1/35.
- Süss J, Klaus C, Gerstengarbe F-W, Werner PC. What makes ticks tick? Climate change, ticks, and tick-borne diseases. *Journal of Travel Medicine* 2008, Volume 15, no 1, 39-45.
- Süss J. Tick-borne encephalitis in Europe and beyond - The epidemiological situation as of 2007. *Eurosurveillance* 2008, Volume 13, no 4-6.
- Süss J. Tick-borne encephalitis 2010: Epidemiology, risk areas and virus strains in Europe and Asia-an overview. *Ticks and tick-borne diseases* 2011, vol 2 no 1, 2-15.

Encéphalite japonaise

Références pour la mise à jour de juin 2018

- Aide-mémoire. Organisation mondiale de la santé. <http://www.who.int/fr/news-room/fact-sheets/detail/japanese-encephalitis> [35]. (Accès 16 mai 2018).
- International Travel and Health, Vaccine-preventable diseases and vaccines. Organisation mondiale de la santé. <http://www.who.int/ith/ITH-Chapter6.pdf?ua=1> [36]. (Accès 16 mai 2018).
- Health Information for International Travel 2018. Centers for Disease Control. <https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/japanese-encephalitis> [37]. (Accès 16 mai 2018).
- Protocole d'immunisation du Québec. MSSS. <http://www.msss.gouv.qc.ca/professionnels/vaccination/protocole-d-immunisation-du-quebec-piq/> [38]. (Accès 16 mai 2018).
- ProMedMail. <http://www.promedmail.org/post/5455667> [39]. (Accès 17 mai 2018).

Références antérieures

- Ayukawa R, Fujimoto H, Ayabe M et al. An unexpected outbreak of Japanese encephalitis in the Chugoku district of Japan, 2002. *Jpn J Infect Dis* 2004; 57 : 63-66.
- Buhl MR, Black FT, Andersen PL, Laursen A. Fatal Japanese encephalitis in a Danish tourist visiting Bali for 12 days. *Scand J Infect Dis* 1996; 28 : 189.
- Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV). Déclaration sur le vaccin contre l'encéphalite japonaise. *RMTC* 1998 : 24.
- Igarashi A, Tanaka M, Morita K et al. Detection of west Nile and Japanese encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan. *Microbiol Immunol* 1994; 38(10) : 827-830.
- Japanese encephalitis on the Australian mainland. *Comm Dis Intell* 1998 May 14; 22(5).
- Johansen C et al. The search for Japanese encephalitis virus in the western province of Papua New

- Guinea, 1996. *Arbovirus Res Aust* 1997; 7 : 131-136.
- Konishi E, Shoda M, Kondo T. Prevalence of antibody to Japanese encephalitis virus non-structural protein among racehorses in Japan: indication of natural infection and need for continuous vaccination. *Vaccine* 2004; 22 : 1097-1103.
 - Konishi E, Suzuki T. Ratios of subclinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. *Vaccine* 2002; 21 : 98-107.
 - Lam K, Tsang OTY, Yung RWH, Lau KK. Japanese encephalitis in Hong Kong. *Hong Kong Med J* 2005; 11 : 182-188.
 - Mackenzie JS, Broom AK, Hall RA et al. Arbovirus in the Australian region, 1990 to 1998. *Comm Dis Intell* 1998; 22 : 93-100.
 - Mackenzie JS et al. Emergence of Japanese encephalitis virus in the Australian region. In Saluzzo JF, Doded B, dir. de la rédaction. *Factors in the emergence of arbovirus diseases*. Paris, Elsevier, 1997; 191-201.
 - Mackenzie JS. Japanese encephalitis : an emerging disease in the Australian region and its potential risk to Australia. *Arbovirus Res Aust* 1997; 7 : 166-170.
 - Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers : exploring the limits of risk. *Clin Infect Dis* 2002; 35 : 183-188.
 - Spicer PE. Japanese encephalitis in Western Irian Jaya. *J Travel Med* 1997; 4 : 146-147.
 - Wittesjö B, Eitrem R, Niklasson B et al. Japanese encephalitis after a 10-day holiday in Bali. *Lancet* 1995; 345 : 856.

Exposition professionnelle au VIH

- CDC. Updates U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. *MMWR* 2005;54(RR-9).
- Smith, D.K., Grohskopf, L.A., Black, R.J., et collab. (2005) Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. *MMWR Recomm Rep*, 54(RR-2), 1-20. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5402a1.htm> [40]
- Panlilio, A.L., Cardo, D.M., Grohskopf, L.A., et collab. (2005) Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. *MMWR Recomm Rep*, 54(RR-9), 1-17. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm> [41]
- Fiore, A.E., Shay, D.K., Broder, K., et collab. (2008) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. *MMWR Recomm Rep*, 57(RR-7), 1-60. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5707a1.htm> [42]
- Bruneau, A., Baril, J.G., Dupont, M., et collab. (2011) Guide pour la prophylaxie postexposition (PPE) à des liquides biologiques dans le contexte du travail, Ministère de la Santé et des Services sociaux, 65 p. <http://publications.msss.gouv.qc.ca/msss/document-000582/> [43]

- Kuhar, D.T., Henderson, D.K., Struble, K.A., et collab. (2013) Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. *Infect Control Hosp Epidemiol*, 34(9), 875-92. <http://stacks.cdc.gov/view/cdc/20711> [44]
- AIDSinfo - Offering information on HIV/AIDS Treatment, Prevention, and Research <https://aidsinfo.nih.gov/> [45]
- Guide thérapeutique VIH/VHC, Feuillet des antirétroviraux, <http://www.guidetherapeutiquevih.com/feuillet-antiretroviraux.asp> [46]
- The University of Liverpool, <http://www.hiv-druginteractions.org/> [47]

Fièvre jaune

- Background Consultation on Yellow Fever and International Travel 2010 (update February 2011). Informal Working Group on Geographic Risk of Yellow Fever. <http://www.who.int/ith/YFrisk.pdf> [48].
- CDC. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001. *MMWR* 2001; 50(30) : 643-645.
- CDC Health Information for International Travel. Centers for Disease Control 2012, Atlanta. <http://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm> [49].
- Cetron M. New data on adverse effects of yellow fever vaccine. Rapport de la 8e conférence de l'ISTM, New York, 2003. (SY09.01).
- Chastel C. Reflection on 2 current viral diseases : yellow fever and dengue. *Ann Biol Clin (Paris)* 1997 Sep-Oct; 55(5) : 415-24.
- Country list: 2017 updates in English, 2016 updates in other languages <http://www.who.int/ith/2017-ith-country-list.pdf?ua=1> [50]
- Déclaration sur la fièvre jaune à l'intention des voyageurs. Comité consultatif de la médecine tropicale et de la médecine des voyages, Relevé des maladies transmissibles au Canada, octobre 2010, vol. 36, DCC-11. <http://www.phacaspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-11/pdf/yf-fj.pdf> [51].
- Fontenille D, Diallo M, Mondo M, Ndiaye M, Thonnon J. First evidence of natural vertical transmission of yellow fever virus in *Aedes aegypti*, its epidemic vector. *Trans R Soc Trop Med Hyg* 1997 Sep-Oct; 91(5) : 533-5.
- Foster KR, Jenkins MF, Toogood AC. The Philadelphia yellow fever epidemic of 1793. *Sci Amer* 1998 Aug; 279(2) : 88-93.
- International travel and Health, 2012 Edition, Genève. <http://www.who.int/ith/en> [52]
- Keystone JS, Dismukes R, Sawyer L, Kozarsky PE. Inadequacies in health recommendations provided for international travelers by North American travel health advisors. *J Travel Med* 1994 Jun

1; 1(2) : 72-78.

- Martin M, Tsai TF, Cropp B et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination : a report of four cases. *Lancet* 2001; 358 : 98-104.
- Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, Cetron MS and the GeoSentinel yellow fever working group. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. *Emerg Infect Dis* 2001; 7(6) : 945-951.
- McFarland JM, Baddour LM, Nelson JE, Elkins SK, Craven RB, Cropp BC, Chang GJ, Grindstaff AD, Craig AS, Smith RJ. Imported yellow fever in a United States citizen. *Clin Infect Dis* 1997 Nov; 25(5) : 1143-7.
- Ministerio da Saude (Ministère de la santé du Brésil). FUNASA. Febre amarela silvestre. *Boletim eletronico epidemiologico* 2001; 1(1) : 4. <http://www.funasa.gov.br/pub/pub00.htm#> [53].
- Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. *Clin Infect Dis* 2002; 34 : 1369-1378.
- Nishioka S de A, Nunes-Araujo FR, Pires WP, Silva FA, Costa HL. Yellow fever vaccination during pregnancy and spontaneous abortion : a case-control study. *Trop Med Int Health* 1998 Jan; 3(1) : 29-33.
- OMS. Fièvre jaune. Réunion technique de consensus, Genève, 2-3 mars 1998. Genève, OMS, 1999.
- OMS. International travel and health. Country list. Vaccination requirements and malaria situation. <http://www.who.int/ith/countries/en/> [54]. Accès le 11 août 2006.
- Sanders EJ, Marfin AA, Tukei PM, Kuria G, Ademba G, Agata NN, Ouma JO, Cropp CB, Karabatsos N, Reiter P, Moore PS, Gubler DJ. First recorded outbreak of yellow fever in Kenya, 1992-1993. I. Epidemiologic investigations. *Am J Trop Med Hyg* 1998 Oct; 59(4) : 644-9.
- Temporary Yellow Fever vaccination requirements for International Travellers related to current outbreaks in Africa, WHO. <http://www.who.int/ith/updates/20160725/en/> [55]. Accès 28 juillet 2016.
- The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Jentes ES et al., for the Informal WHO Working Group on Geographic Risk for Yellow Fever. *Lancet Infect Dis*. Août 2011, n° 11, vol. 8, p 622-632.
- Tolou H, Pisano MR, Durand JP. Molecular epidemiology of yellow fever, *Med Trop (Mars)* 1998; 58 (2 Suppl) : 37-41.
- Voyages internationaux et santé. Organisation mondiale de la santé 2011, Genève. <http://www.who.int/ith/fr/index.html> [56].
- Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morbidity and Mortality Weekly Report*, 30 juillet 2010, vol. 59, no RR—7, pp. 1 - 27. <http://www.cdc.gov/mmwr/pdf/rr/rr5907.pdf> [57].

Hépatites A et B

- Agboatwalla M, Isomura S, Miyake K, Yamashita T, Morishita T, Akram DS. Hepatitis A, B and C seroprevalence in Pakistan. *Indian J Pediatr* 1994 Sep-Oct; 61 (5) : 545-9.

- Anis E, Leventhal A, Roitman M, Slater PE. Introduction of routine hepatitis A immunization in Israel - the first in the world. Dept. of Epidemiology and Public Health Services, Israel Ministry of Health, Jerusalem. Harefuah 2000 Feb 1;138(3) : 177-80, 272.
- Barros H, Oliveira F, Miranda H. A survey on hepatitis A in Portuguese children and adolescents. J Viral Hepat 1999 May; 6(3) : 249-53.
- Beran J, Douda P, Rychly R. Seroprevalence of viral hepatitis A in the Czech Republic. Eur J Epidemiol 1999 Oct;15(9) : 805-8.
- Brown MG, Lindo JF, King SD. Investigations of the epidemiology of infections with hepatitis A virus in Jamaica. Ann Trop Med Parasitol 2000 Jul;94(5) : 497-502.
- Cianciara J. Hepatitis A shifting epidemiology in Poland and Eastern Europe. Vaccine 2000 Feb 18;18 Suppl 1(4) : S68-70.
- Comité consultatif national de l'immunisation (CCNI). Déclaration supplémentaire sur la prévention de l'hépatite A. RMTC 1996; 22 (1) : 1-3.
- Comité consultatif national de l'immunisation (CCNI). Déclaration relative à la prévention de l'hépatite A. RMTC 1994; 20 (16) : 133-143.
- Dalekos GN et al. Prevalence of viral markers among refugees from southern Albania : increased incidence of infection with hepatitis A, B and D viruses. Eur J Gastroenterol Hepatol 1995 juin; 7 (6) : 553-8.
- Da Villa G, Andjaparidze A, Cauletti M, Franco E, Roggendorf M, Sepe A, Zaratti L. Viral hepatitis in the Bhutanese population : preliminary results of a seroepidemiological investigation. Res Virol 1997 Mar-Apr; 148 (2) : 115-7.
- Dowe G, King SD, Smikle MF, Wynter HH, Chout R, Klaskala W. Prevalence of viral and bacterial sexually transmitted pathogens in Jamaican pregnant women. West Indian Med J 1998 Mar; 47 (1) : 23-5.
- Dulat C, Defrance JP, Ille H. Statut immunologique des militaires d'origine antillaise vis-à-vis du virus de l'hépatite A : incidence sur la prophylaxie. Med Trop (Mars) 1996;56(3) : 255-8.
- Edmunds WJ, Medley GF, Nokes DJ, O'Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 1996 Oct; 117 (2) : 313-25.
- FitzSimons D, Van Damme P. Prevention and control of hepatitis B in central and eastern Europe and the Newly Independent States, Siofok, Hungary, 6-9 October 1996. Vaccine 1997; 15 (15) : 1595-7.
- Fock KM et al. Seroprevalence of antibodies against hepatitis A (anti-HAV) in Singapore : the NFDD experience. Singapore Med J 1995 fév.; 36 (1) : 26-7.
- Gdalevich M, Grotto I, Mandel Y, Mimouni D, Shemer J, Ashkenazi I. Hepatitis A antibody prevalence among young adults in Israel - the decline continues. Epidemiol Infect 1998 Oct; 121 (2) : 477-9.
- Green MS, Aharonowitz G, Shohat T, Levine R, Anis E, Slater PE. The changing epidemiology of viral hepatitis A in Israel. Isr Med Assoc J 2001 May;3(5) : 347-51
- Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38 Suppl 2 : S18-23.
- Hadjipanayis A, Hadjichristodoulou C, Kallias M, Sava K, Petsa A, Demetriadou K, Christodoulou C, Constantinou A, Sidera M. Prevalence of antibodies to hepatitis A among children and adolescents in Larnaca area, Cyprus. Eur J Epidemiol 1999 Nov;15(10) : 903-5.
- Hernandez F, Monge R, Jimenez C, Taylor L. Rotavirus and hepatitis A virus in market lettuce (*Latuca sativa*) in Costa Rica. Int J Food Microbiol 1997 Jul 22; 37 (2-3) : 221-3.
- Howitz M, Mazick A, Mølbak K. Hepatitis A outbreak in a group of Danish tourists returning from Turkey, October 2005. Eurosurveillance Weekly December 1, 2005. 12(12).
<http://www.eurosurveillance.org/ew/2005/051201.asp#2> [58]
- Irshad M, Joshi YK, Acharya SK, Tandon BN. Prevalence of hepatitis B virus infection in healthy

persons in North India. *Natl Med J India* 1994 Sep-Oct; 7 (5) : 210-2.

- Jong EC. Immunizations for international travel. *Infectious Disease Clinics of North America* juin 1998; 12 (2) : 249-266.
- Larouzé B, Bouchaud O, Dazza MC, Samb B. Prévention des hépatites virales chez les voyageurs et les expatriés en milieu tropical et subtropical. *Rev Épidém et Santé Publ* 1998; 46 : 56-62.
- Lionis C, Frangoulis E, Koulentakis M, Biziagos E, Kouroumalis E. Prevalence of hepatitis A, B, and C markers in school children of a rural area of Crete, Greece. *Eur J Epidemiol* 1997 Jun; 13 (4) : 417-20.
- Lonergan G. Epidemiology of hepatitis A in Montreal travelers. 5th International Conference on Travel Medicine, 24-27 mars 1997, Genève.
- Malamitsi-Puchner A et al. Prevalence study of different hepatitis markers among pregnant Albanian refugees in Greece. *Eur J Epidemiol* juin 1996; 12 (3) : 297-301.
- Marinho RT, Valente AR, Ramalho FJ, de Moura MC. The changing epidemiological pattern of hepatitis A in Lisbon, Portugal. *Eur J Gastroenterol Hepatol*. 1997 Aug;9(8) : 795-7.
- Mazokopakis E, Vlachonikolis J, Philalithis A, Lionis C. Seroprevalence of hepatitis A, B and C markers in Greek warship personnel. *Eur J Epidemiol* 2000;16(11) : 1069-1072
- Mittal SK, Rao S, Rastogi A, Aggarwal V, Kumari S. Hepatitis B - potential of perinatal transmission in India. *Trop Gastroenterol* 1996 Jul-Sep; 17 (3) : 190-2.
- Paquet C et al. Viral hepatitis in Bucharest. *Bull World Health Organ* 1993; 71 (6) : 781-6.
- Perez OM, Morales W, Paniagua M, Strannegard O. Prevalence of antibodies to hepatitis A, B, C, and E viruses in a healthy population in Leon, Nicaragua. *Am J Trop Med Hyg* 1996 Jul; 55 (1) : 17-21.
- Polz-Dacewicz MA, Policzekiewicz P, Badach Z. Changing epidemiology of hepatitis A virus infection - a comparative study in central eastern Poland (1990-1999). *Med Sci Monit* 2000 Sep-Oct;6(5) : 989-93.
- Rumi MA, Begum K, Hassan MS, Hasan SM, Azam MG, Hasan KN, Shirin M, Khan AK. Detection of hepatitis B surface antigen in pregnant women attending a public hospital for delivery : implication for vaccination strategy in Bangladesh. *Am J Trop Med Hyg* 1998 Aug; 59 (2) : 318-22.
- Schmunis GA, Zicker F, Pinheiro F, Brandling-Bennett D. Risk for transfusion-transmitted infectious diseases in Central and South America. *Emerg Infect Dis* 1998 Jan-Mar; 4 (1) : 5-11.
- Sikorska K et al. An epidemiologic assessment of viral hepatitis type A morbidity in the Gdansk province in the years 1989-1990. *Przegl Epidemiol* 1993; 47 (3) : 225-33.
- Smikle M, Dowe G, Hylton-Kong T, Williams E. Hepatitis B and C viruses and sexually transmitted disease patients in Jamaica. *Sex Transm Infect* 2001 Aug;77(4) : 295-296.
- Steffen R. et al. Epidemiology and prevention of hepatitis A in travelers. *JAMA* 1994; 272 (11) : 885-9.
- Steffen R. Epidemiologic basis for the practice of travel medicine. *J Wilderness Med* 1994; 5 : 56-66.
- Steffen R. Hepatitis A and hepatitis B : risks compared with other vaccine preventable diseases and immunization recommendations. *Vaccine* 1993; 11 (5) : 518-20.
- Steffen R. Immunization against hepatitis A and hepatitis B infections. *J Travel Med* 2001; 8(Suppl 1) : S9-S16
- Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, Van Damme P. Epidemiology and prevention of hepatitis A in travelers. *JAMA* 1994; 271 : 885-889.
- Stroffolini T, Mele A, Tosti ME, Gallo G, Balocchini E, Ragni P, Santonastasi F, Marzolini A, Ciccozzi M, Moiraghi A. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. *J Hepatol* 2000 Dec; 33(6) : 980-5.
- Tandon BN, Acharya SK, Tandon A. Epidemiology of hepatitis B virus infection in India. *Gut* 1996; 38 Suppl 2 : S56-9.
- Tufenkeji H. Hepatitis A shifting epidemiology in the Middle East and Africa. *Vaccine*. 2000 Feb

18;18 Suppl 1 : S65-7.

- Viel JF, Fest T, Dussaucy A, Pobel D, Agis F. Hepatitis B virus infection on a tropical island : sociodemographic and geographic risk factors in Guadeloupe. Am J Trop Med Hyg 1995 May; 52 (5) : 398-402.
- Withers BG, Kelley PW, Pang LW, Kustermann JA, MacArthy PO, Russell BJ, Pallansch MA. Vaccine-preventable disease susceptibility in a young adult Micronesian population. Southeast Asian J Trop Med Public Health 1994 Sep; 25 (3) : 569-74.
- Wong DC, Purcell RH, Rosen L. Prevalence of antibody to hepatitis A and hepatitis B viruses in selected populations of the South Pacific. Am J Epidemiol 1979 Sep; 110 (3) : 227-36.

Infections invasives à méningocoque

- Agence de Santé publique du Canada. Méningococcie. Sur <http://www.phacaspc.gc.ca/tmp-pmv/meningitis-fra.php> [59] . Mise à jour Janvier 2011. Vu le 23 janvier 2012.
- Bhatt, K.M. et al. Meningococcal meningitis. East African Medical Journal janvier 1996; 73 (1) : 35-9.
- CDC. Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia-United States 2000. MMWR 2000; 49(16) : 345-346.
- Centers for Disease Control and Prevention. Infectious Diseases related to Travel (chap 3). Yellow Book. 2012. <http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/meningococcal-disease.htm> [60]. Vu le 26 janvier 2012.
- Comité consultatif de la médecine tropicale et de la médecine des voyages. Déclaration sur la vaccination des voyageurs contre le méningocoque. RMTc 1999; 25-DDC-5.
- Nicolas, P. Épidémie de méningite à méningocoque en Afrique en 1996 : données actuelles. Médecine tropicale, 56 (2) : 203-4, 1996.
- OMS. Lutte contre les épidémies de méningite à méningocoque : guide pratique OMS. Genève, OMS, 1998. WHO/EMC/BAC/98.3. <http://www.who.int/emc> [61] , accès le 11 avril 2000.
- OMS. Outbreak News Index - Meningococcal disease. Genève, OMS. http://www.who.int/emc/outbreak_news/diseases_indices/men_index.html [62] , accès le 12 avril 2000.
- OMS. Scientists mark “stunning success” of vaccine in virtually ridding Africa of meningitis A (OMS) http://www.who.int/immunization/newsroom/press/news_release_3_nov_2015_meningitis_a/en/ [63]
- Relevé des maladies transmissibles au Canada (RMTc): Volume 41-05, 7 mai 2015 <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/15vol41/dr-rm41-05/com-2-fra.php> [64]
- Riedo, F. et al. Epidemiology and prevention of meningococcal disease. Pediat Infect Dis J 1995; 14-643-57.
- Santé Canada. Agence canadienne de santé publique. Information sur la maladie – la méningococcie. http://www.phac-aspc.gc.ca/tmp-pmv/info/meningitis_f.html [65]
- Travel Health Online; <http://www.tripprep.com/scripts/main/default.asp> [66] (révisé 2005-02-22).
- Tikhomirov E, Santamaria M, Esteves K. Meningococcal disease : public health burden and control. Rapp trimest sanit mond 1997; 50 : 170-176.

<http://www.who.int/emc/diseases/meningitis/meningart.pdf> [67] , accès le 18 avril 2000.

- Weekly epidemiological record No. 47, 2015, 90, p633-644
<http://www.who.int/wer/2015/wer9047.pdf> [68]
- Weekly epidemiological record No. No. 13, 2015, 90, p121-132
<http://www.who.int/wer/2015/wer9013.pdf> [69]
- World Health Statistics 2015 (OMS)
http://apps.who.int/iris/bitstream/10665/170250/1/9789240694439_eng.pdf?ua=1&ua=1 [70]

Influenza

- Freedman DO, Leder K. Influenza : changing approaches to prevention and treatment in travellers. *Journal of Travel Medicine* 2005; 12 : 36-44.
- Santé Canada, Agence de santé publique du Canada : surveillance de l'influenza.
http://www.phac-aspc.gc.ca/fluwatch/index_f.html [71] .
- Santé Canada, Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV), Comité consultatif national de l'immunisation (CCNI). Voyages, grippe et prévention. *RMTC* 1er septembre 1996; 22(17).
- Santé Canada, Comité consultatif national de l'immunisation (CCNI). Déclaration sur la vaccination anti-grippale pour la saison 2004-2005. *RMTC* 15 juin 2004; 30 : DCC-3.
- Santé Canada, Programme de médecine des voyages. Grippe et voyages : bateaux de croisière et voyages organisés par voie de terre. 6 juin 2000.
http://www.hc-sc.gc.ca/pphb-dgspsp/tmp-pmv/2000/cruzpr_f.html [72] .
- Santé Canada, Programme de médecine des voyages, conseils de santé aux voyageurs : Influenza aviaire A (H5N1) : activité chez les humains en Asie. Mise à jour 3 février 2005.
http://www.phac-aspc.gc.ca/tmp-pmv/2005/h5n1050203_f.html [73].
- Steffen R, Connor BA. Vaccines in travel health : from risk assessment to priorities. *Journal of Travel Medicine* 2005; 12 : 26-35.

Leishmaniose

- OMS www.who.int/leishmaniasis/resources/en [74]
- CDC wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel [75]
- Gouvernement du Canada voyage.gc.ca/voyager/sante-securite/maladies/leishmaniose [76]
- IDSA Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). 2016. *CID* 63 p202-264 www.idsociety.org/Organism/#Leishmaniasis [77]

Leptospirose

- McBride JA, Athanazio DA et al. Leptospirosis. *Current Opinion in Infectious Diseases* 2005; 18 376-86.
- OMS. Human leptospirosis : guideline for diagnosis, surveillance and control, 2003.
- Pappas G, Papadimitriou P et al. The globalization of leptospirosis : worldwide incidence trends. *International Journal of Infectious Diseases* 2008; 12 351-7.
- Pavli A, Maltezou HC. Travel-acquired leptospirosis. *Journal of travel medicine* 2008; 15 (6) 447-53

Maladie de Lyme

- Artsob H, Maloney R, Conboy G et coll. Identification d' *Ixodes scapularis* à Terre-Neuve, Canada. RMTC 2000; 26 : 133-134.
- CDC. Case definitions for infectious conditions under public health surveillance. MMWR 1997 ; 46 RR10 : 20-1.
- CDC. Lyme disease - United States 1996, MMWR 1997; 46 (23).
- CDC. Lyme disease - United States 2001-2002. MMWR Morb Mortal Wkly Rep 2004; 53 : 365-369.
- Comité consultatif national de l'immunisation. Déclaration sur la vaccination contre la maladie de Lyme. RMTC 2000; 26 : 1-11.
- Dos Santos C, Kain K. Babébiose et maladie de Lyme concomitantes en Ontario. RMTC 1998 : 24 : 97-101.
- Gauthier M, Laferrière C. La maladie de Lyme : un second cas au Québec. Le Clinicien 1990; 5 : 105-107.
- Lindsay R, Artsob H, Galloway T et coll. Vecteur de la borréliose de Lyme, *Ixodes scapularis*, identifié en Saskatchewan. RMTC 1999; 25 : 81-83.
- Lyme disease. <http://www.cdc.gov/ncidod/diseases/lyme/lyme.htm> [78] (1998).
- Masuzawa T. Terrestrial distribution of the Lyme borreliosis agent *Borrelia burgdorferi* sensu lato in East Asia. Jpn J Infect Dis 2004; 57 : 229-235.
- Morshed MG, Scott JD, Banerjee SN et coll. Premier isolement du spirochète de la maladie de Lyme, *Borrelia burgdorferi*, chez une tique à pattes noires, *Ixodes scapularis*, retrouvée sur un oiseau en Nouvelle-Écosse, Canada. RMTC 1999; 25 : 153-155.
- Morshed MG, Scott JD, Banerjee SN et coll. Premier isolement de *Borrelia burgdorferi*, le spirochète responsable de la maladie de Lyme, chez *Ixodes scapularis*, la tique à pattes noires, au parc provincial Rondeau en Ontario. RMTC 2000; 26 : 42-44.
- Spotlight on Lyme disease. <http://www.cdc.gov/ncidod/dvbid/lymeinfo.htm> [79] (1998).
- Stanek G, Strle F. Lyme borreliosis. Lancet 2003; 362 : 1639-1647.
- Steere AC. Lyme disease. N Engl J Med 2001; 345 : 115-125.
- Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest 2004; 113 : 1093-1101.
- Trudel L, Dion R. Rapport de surveillance des tiques, Institut national de santé publique (INSPQ), Laboratoire de santé publique du Québec (LSPQ), 1990 à 2004.
- Vallière L, Beaudry JM. La maladie de Lyme : un premier cas au Québec. Le Clinicien 1990; 75-81.
- Whealan M, Zoutman D. Lyme disease in North America : a review. Can J Infect Cont 2004 : 80-86.

Paludisme

Nouvelles références pour 2016:

- Agence de santé publique du Canada, Appendix I: Malaria Risk and Recommended Chemoprophylaxis by Geographic Area, 2016 : http://www.phac-aspc.gc.ca/tmp-pmv/malaria_catmat-paludisme_ccmtmv-eng.php [80]
- Centers for Disease Control and Prevention, Yellow book 2016 : <http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/yellow-fever-malaria-information-by-country#select-seldyfm707> [81]
- Organisation mondiale de la Santé, ITH, List of countries and areas, Vaccination requirements and

recommendations for international travellers, including yellow fever and malaria, 2016 :

<http://www.who.int/ith/2016-ith-county-list.pdf?ua=1> [82]

- Organisation mondiale de la santé, World malaria report 2015 :

<http://www.who.int/malaria/publications/world-malaria-report-2015/wmr2015-profiles.pdf?ua=1> [83]

Nouvelles références pour 2015 :

- Recommandations canadiennes pour la prévention et le traitement du paludisme (malaria) chez les voyageurs internationaux; Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV); 2014; site web : <http://www.publications.gc.ca/pub?id=463471&sl=1> [84]
- Déclaration relative aux mesures de protection individuelle pour prévenir les piqûres ou morsures d'arthropodes ; Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV) ; Relevé des maladies transmissibles au Canada ; Volume 38 ; DCC-3 ; Novembre 2012
- Voyages internationaux et santé; Organisation mondiale de la santé (OMS); Mises à jour 2014; site web : http://www.who.int/ith/chapters/ITH_chapter_7fr.pdf?ua=1 [85] et <http://www.who.int/ith/chapters/ithcountrylistFR.pdf?ua=1> [86]
- World Malaria Report 2014; Organisation mondiale de la santé (OMS); site web : http://www.who.int/malaria/publications/world_malaria_report_2014/en/# [87]
- CDC Health Information for International Travel 2014 (Yellow Book); Centers for Disease Control and Prevention; site web : www.nc.cdc.gov/travel/page/yellowbook-home-2014 [88]
- Fit for Travel (Écosse); site web : www.fitfortravel.nhs.uk/home.aspx [89]
- Santé-voyages - Vaccinations et mesures antipaludiques - Recommandations état décembre 2014 (Suisse); Centre de médecine des voyages, Institut de médecine sociale et préventive de l'Université de Zurich ; Bull OFSP 2015; no 1/2/3: S. 13-36
- Institut Pasteur (France); site web : <http://www.pasteur.fr/fr/map> [90]
- Malaria prevention guidelines for travellers from the UK 2014; Public Health England (Angleterre); site web : www.gov.uk/government/uploads/system/uploads/attachment_data/file/337761/Guidelines_for_malaria_prevention_in_travellers_UK_PC.pdf [91]
- Eurosurveillance; site web : www.eurosurveillance.org/ [92]
- ProMED mail; site web : www.promedmail.org/ [93]

Références des éditions antérieures

- Abou-Donia MB et al. Neurotoxicity resulting from coexposure to pyridostigmine bromide, deet and permethrin : implications of Gulf War chemical exposures. J Toxicol Environ Health, mai 1996; 48(1) : 35-56.
- Aylward JM. Hydrochloroquine and chloroquine : assessing the risk of retinal toxicity, J Am Optom Assoc, novembre 1993; 64(11) : 787-97.
- Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004 : 39; 1335-45.
- Baird JK. Chloroquine resistance in Plasmodium vivax. AAC 2004 : 48; 4075-83.
- Balo KP et al. Chloroquine maculopathy and prevention of malaria. J Fr Ophtalmol 1996; 19(12) : 770-6.
- Bartel PR et al. Visual function and long-term chloroquine treatment. S Afr Med J, janvier 1994; 84(1) : 32-4.
- Boggild AK, Parise ME, Lewis LS, Kain KC. Atovaquone-proguanil : report from the CDC expert meeting on malaria chemoprophylaxis (2). American journal of tropical medicine and hygiene 2007, 76 (2) : 208-23.

- Boudreau E et al. Tolerability of prophylactic Lariam regimens. Trop Med and Parasitol, septembre 1993; 44(3) : 257-65.
- Brown M, Hebert AA. Insect repellents an overview. Journal of American Academic Dermatology, février 1997; 36 (2PT1) : 243-9.
- Cox NH, Paterson WD. Ocular toxicity of antimalarials in dermatology : a survey of current practice. Br J Dermatol, Décembre 1994; 131(6) : 878-82.
- Durrheim DN et al. Accuracy of a rapid immunochromatographic card test for *Plasmodium falciparum* in a malaria control programme in South Africa. Transactions of the Royal Society of Tropical Medicine 1998; 92 : 32-33.
- Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002; 347(1) : 13-18.
- Fryauff DJ et al. Malaria in a non immune population after extended chloroquine or primaquine prophylaxis, Am J Trop Med Hyg, février 1997, 56(2) : 137-40.
- Garner P, Brabin B. A review of randomized controlled trials of routine antimalarial drug prophylaxis during pregnancy in endemic malarious areas. Bull OMS 1994; 72(1) : 89-99.
- GlaxoSmithKline Inc. Monographie du Malarone®. Mississauga, GlaxoSmithKline Inc. 2001 (revision 2002), 39 pages.
- Goodman and Gilman's. The pharmacological basis of therapeutics, 9e éd. McGraw-Hill, 1996, 1905 pages.
- Goodyer L, Behrens RH. Short report : the safety and toxicity of insect repellents. Am J Trop Med Hyg 1998; 59(2) : 323-324.
- Grierson DJ. Hydrochloroquine and visual screening in a rheumatology outpatient clinic. Annals of the Rheumatic Diseases, mars 1997; 56(3) : 188-90.
- Hoffmann-La Roche Limitée. Monographie du Lariam®. Mississauga, Hoffmann- La Roche Limitée. 1993 (revision 2002), 14 pages.
- Hogg B, Clarke PD, Camus D et al. Atovaquone-proguanil versus chloroquineproguanil for malaria prophylaxis in non-immune travellers : a randomised double-blind study. Lancet 2000; 356 : 1888-1894.
- International Association for Medical Assistance to Travellers (IAMAT). How to protect yourself against malaria. Guelph, IAMAT, 2003.
- Jong EC, Nothdurft HD. Current drugs for antimalarial chemoprophylaxis : a review of efficacy and safety. J Travel Med 2001; 8(Suppl 3) : S48-S56.
- Kain KC, Keystone JS. Malaria in travelers : Epidemiology disease and prevention, Infectious Diseases Clinics of North America, juin 1998; 12(2) : 267-287.
- Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin Infect Dis 2001; 33 : 226-234.
- Labbé AC et al. Recent advances in the prophylaxis and treatment of malaria. Curr Infect Dis Rep 2001; 3 : 68-76.
- Lange WR et al. No evidence for chloroquine associated retinopathy among missionaries on long-term malaria chemoprophylaxis. Am J Trop Med Hyg, octobre 1994; 51(4) : 389-92.
- Lell B et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351 : 709-713.
- Lell B et al. A randomized, double-blind, placebo-controlled study to evaluate the suppressive prophylactic activity of atovaquone plus proguanil (Malarone™) in children at risk of developing Plasmodium falciparum infection. Am J Trop Med Hyg 1997; 57 (S3) : S103-104, abstract no 8.
- Lobel HO, Kozarsky PE. Update on prevention of malaria for travelers. JAMA 3 décembre 1997; 278(21) : 1767-1771.
- MacLean JD, Demers A-M, Ndao M, Kokoskin E, Ward BJ, Gyorkos TW. Malaria epidemics and

surveillance systems in Canada. *Emerg Infect Dis* 2004 ; 10; 1195-2001.

- Meshnick SR. Artemisinin : mechanisms of action, resistance and toxicity. *Int J Parasitol* 2002; 32(13) : 1655-60.
- Ministerio de salud del Peru (Ministère de la santé du Pérou) – Dirección general de epidemiología. Malaria general-Peru, hasta semana 24-2006. <http://www.oge.sld.pe/Asis/sala/semana/malaria.pdf> [94].
- Nosten F. et al. Mefloquine prophylaxis prevents malaria during pregnancy : A double-blind, placebo-controlled study. *J Infect Dis* 1994; 169 : 595-603.
- Ochsendorf FC, Runne U. Chloroquine : consideration of maximum daily dose (3.5mg/kg ideal body weight) prevents retinopathy. *Dermatology*, 1996; 192-(4) : 382-3.
- OMS. Guidelines for the treatment of malaria. Genève, OMS, 2006.
- OMS. International travel and health. Country list. Vaccination requirements and malaria situation. <http://www.who.int/ith/countries/en/> [54] . Accès le 11 août 2006.
- Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC and the Malarone International Study Team. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers : results from a randomised, double-blind study. *Clin Infect Dis* 2001; 33 : 1015-1021.
- Phillips-Howard PA et Wood D. The safety of antimalarial drugs in pregnancy. *Drug - Saf*, mars 1996; 14(3) : 131-45.
- Phillips-Howard PA, Ter-Kuile FO. CNS adverse events associated with antimalarial agents. Fact of fiction? *Drug-Saf*, juin 1995; 12(6) : 370-83.
- Rynes RI. Ophthalmologic considerations in using antimalarials in the United States. *Lupus*, juin 1996; 5 Suppl 1 : 73-4.
- Santé Canada. Conseils de sécurité concernant l'utilisation d'insectifuges personnels. Avril 2003. http://www.hc-sc.gc.ca/francais/virus_nil/insectifuge.html [95].
- Santé Canada. Recommandations canadiennes pour la prévention et le traitement du paludisme (malaria) chez les voyageurs internationaux. *RMTC* 2004; 30(S1) : 1-66.
- Schlaughenhauf, P. Traveler's malaria. Hamilton (Ontario), BC Decker, 2001.
- Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria implications for chemoprophylaxis in travelers. *NEJM* 2003; 349 : 1510-6.
- Shanks GD. et al. Effectiveness of doxycycline combined with primaquine for malaria prophylaxis. *Med J Aust*, mars 1995; 20, 162(6) : 306-7, 309-10.
- Shanks GD et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for *Plasmodium falciparum* malaria. *Clin Infect Dis* 1998; 27 : 494-499.
- Smoak BL et al. The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army Service Women. *J Infect Dis* 1997; 176 : 831-3.
- Soto J, Toledo J, Rodriguez M et al. Double-blind, randomized, placebocontrolled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. *Clin Infect Dis* 1999; 29 : 199-201.
- Spalton DJ. Retinopathy and antimalarials drugs : The British experience. *Lupus*, juin 1996, 5 Suppl 1 : 570-2.
- Steketee RW et al. Malaria treatment and prevention in pregnancy : indications for use and adverse events associated with use of chloroquine or mefloquine. *Am J Trop Med Hyg* 1996; 55 (1 suppl) : 50-6.
- Travel Medicine Advisor. Update on malaria, prophylaxis and treatment from the ASTMH Meeting. January/February 1998 : 3-5.
- Van Hensbroek MB et al. A trial of artemether or quinine in children with cerebral malaria. *N Engl J Med*, 11 juillet 1996; 335(2) : 69-75.
- Vanhauwere B et al. Postmarketing surveillance of prophylactic mefloquine (Lariam®). Use in

Pregnancy. Am J Trop Med Hyg 1998 : 17-21.

- Van Vugt M, Ezzet E, Nosten F, Gathmann L, Wilairatana P, Looareesuwan S, White NJ. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med 1999; 61 : 964-7.
- Weiss Walter R et al. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: Comparaison with mefloquine, doxycycline and chloroquine plus proguanil. J Infect Dis 1995; 171 : 1569-75.
- Yeo AE. et Rieckmann KH. The activity of triple combinations of antifolate biguanides, with and without folinic acid, against Plasmodium falciparum in vitro. Am Trop Med Parasitol, avril 1997; 91(3) : 247-251.

Poliomyélite

Références pour la révision avril 2017:

- The Global Polio Eradication Initiative : <http://www.polioeradication.org> [96].
<http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx> [97].
- International Travel and Health (World Health Organisation, 2017 update) : <http://www.who.int/ith/2017-ith-country-list.pdf?ua=1> [50]
- Ministère de la santé de l'Arabie Saoudite : <http://www.moh.gov.sa/en/HealthAwareness/Hajj/Pages/005.aspx> [98]

Références des éditions antérieures:

- CDC. Progress toward interruption of wild poliovirus transmission-Worldwide, January 2004-March 2005. MMWR 2005; 54 : 408-412.
- Heymann D, Aylward RB. Eradicating polio. New Engl J Med 23 sept 2004; 351(13) : 1275-1277.
- Ministère de la santé du Japon. Poliomyelitis, Japan, 1962-1995. Infectious agents surveillance report (IASR) Jan 1997, 18(1).
- OMS. Certification de l'éradication de la poliomyélite, région OMS du Pacifique occidental, octobre 2000. Relevé épidémiol hebdo déc 2000; 75(49) : 339-340.
- OMS. Disease outbreak news. Archives by disease. Poliomyelitis. <http://www.who.int/csr/don/archive/disease/poliomyelitis/en/> [99] Accès le 21 juillet 2005.
- OMS. Initiative mondiale pour l'éradication de la poliomyélite-Rapport annuel 2004. Mai 2005, WHO/Polio/05.03F
- OMS. Fonctionnement de la surveillance de la paralysie flasque aiguë (PFA) et incidence de la poliomyélite, 1997-1998. Relevé épidémiol hebdo 1998; 73 :217-220.
- OMS-Global polio eradication initiative. Country risk profiles. OMS, Genève, 2005. <http://www.polioeradication.org/features/countryprofiles/countries.asp#B> [100]. Accès le 25 juillet 2005.
- Sutter RW et al. Poliomyelitis eradication : progress, challenges for the end game, and preparation for the post-eradication era. Infect Dis Clin North Am 2001; 15(1) : 41-64.
- Wood DJ, Sutter RW, Dowdle WR. Stopping poliovirus after eradication : issues and challenges. Bull OMS 2000; 78(3) : 347-363.

Rage

Nouvelles références pour l'édition 2015 :

- Centers for Diseases Control and Prevention (CDC). (2014). Travelers' Health - Yellow Book. Disponible sur: <http://wwwnc.cdc.gov/travel/page/yellowbook-home> [101]
- Keystone, J.S. (2014). Travel medicine. London : Mosby Elsevier.
- Ministère de la Santé et des Services sociaux du Québec. (2012). Guide d'intervention visant la prévention de la rage humaine. Québec: Direction des communications du ministère de la Santé et des Services sociaux.
- Ministère de la Santé et des Services sociaux du Québec. (2009). Protocole d'immunisation du Québec, 6e édition, mises à jour 2015. Québec: Direction des communications du ministère de la Santé et des Services sociaux du Québec. Disponible sur: <http://publications.msss.gouv.qc.ca/acrobat/f/documentation/piq/html/web/Piq.htm> [102]
- Organisation Mondiale de la Santé. (2012). Voyages internationaux et santé, mise à jour 2014. Genève: Auteur. Disponible sur: <http://www.who.int/ith/fr/> [103]
- Site internet : <http://www.oie.int/fr/> [104]

Références des éditions antérieures :

- Centers for Disease Control and Prevention. Infectious Diseases Related to Travel (chapter 3). In Traveler's health (Yellow Book). Oxford Unity Press Editor. 2012
<http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/rabies.htm> [105]
<http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/rabies> [106].
- Children's Hospital Boston. HealthMap <http://healthmap.org/fr> [107].
- Comité consultatif de la médecine tropicale et de la médecine des voyages. Déclaration relative aux voyageurs et au vaccin contre la rage. RMCT mars 2002; DCC-4.
<http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/02vol28/28sup/dcc4.html> [108].
- Institute of epidemiology. WHO collaborating center. Friedrich Loeffler Institute. Federal Institute for Animal Health, Wusterhausen, Allemagne. Rabies Bulletin Europe 2008.
<http://www.who-rabies-bulletin.org> [109] , accès 17 mars 2009.
- Ministère de la Santé et des Services sociaux du Québec. Protocole d'immunisation du Québec. Avril 2009. P. 355-363
http://publications.msss.gouv.qc.ca/acrobat/f/documentation/piq/chap10-7_rage.pdf [110].
- Organisation mondiale de la santé. Rabies. Fact sheet no. 99. Media Center, September 2011
<http://www.who.int/mediacentre/factsheets/fs099/en> [111].
- Organisation mondiale de la santé. Rabies : A neglected zoonotic disease. 2012
<http://www.who.int/rabies/en> [112].
- Organisation mondiale de la santé. WHO recommended standards and strategies for surveillance, prevention and control of communicable diseases.
<http://www.who.int/rabies/epidemiology/Rabiessurveillance.pdf> [113].
- Organisation mondiale de la santé . Vaccins anti-rabiques : note d'information de l'OMS. Relevé épidémiologique hebdomadaire. No 32, 6 août 2010, p. 309-320
<http://www.who.int/wer/2010/wer8532.pdf> [114].
- Organisation mondiale de la santé animale (OIE). Detailed country (ies) disease incidence.

http://www.oie.int/wahis/public.php?page=disease_status_detail [115] , accès le 16 mars 2009.

- OMS. Human and animal rabies. <http://www.who.int/rabies/en> [112].
- Plotkin S, Orenstein WA, Offit P, Vaccines, 5e ed. Philadelphia, Saunders-Elsevier, 2008.

Rougeole

- L'élimination de la rougeole. Relevé des maladies transmissibles au Canada, vol 41 (7), 2 juillet 2015. <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/15vol41/dr-rm41-07/ar-01-fra.php> [116]
- Bilan final de l'épidémie provinciale de rougeole survenue en 2011. MSSS.
- http://www.msss.gouv.qc.ca/professionnels/documents/rougeole/etat_situation.pdf [117]
- Écllosion de rougeole dans Lanaudière. Bulletin Flash Vigie, vol 10 (2), février-mars 2015. http://publications.msss.gouv.qc.ca/msss/fichiers/flashvigie/06-271-02W-vol10_no2.pdf [118]

Documents de l'Organisation mondiale de la santé et de l'Organisation panaméricaine de la santé :

- Rougeole, Aide-mémoire, mars 2016. <http://www.who.int/mediacentre/factsheets/fs286/fr/> [119]
- International and Health. <http://www.who.int/ith/vaccines/measles/en/> [120]
- WHO-UNICEF estimates of MCV2 coverage. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragemcv2.html [121]
- Immunizations, Vaccines and Biologicals, Measles. http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles/en/ [122]
- Global and regional immunization profiles, Region of the Americas. http://www.who.int/immunization/monitoring_surveillance/data/g_s_amrprofile.pdf?ua=1 [123]
- Epidemiological Alert, Measles outbreaks and implications for the Americas, 9 février 2015. http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gid=29016&lang=en [124]
- Measles Weekly Bulletin. http://www.paho.org/hq/index.php?option=com_topics&view=rdrmore&cid=8321&Itemid=40899&lang=en [125]
- WHO EpiBrief, janvier à décembre 2015. <http://www.euro.who.int/en/health-topics/communicable-diseases/measles-and-rubella> [126]
- Eliminating measles and rubella, Framework for the verification process in the WHO European region 2014. http://www.euro.who.int/_data/assets/pdf_file/0009/247356/Eliminating-measles-and-rubella-Framework-for-the-verification-process-in-the-WHO-European-Region.pdf?ua=1 [127]
- 4th Meeting of the European Regional Verification Commission for Measles and Rubella Elimination, octobre 2015. http://www.euro.who.int/_data/assets/pdf_file/0011/304958/4th-RVC-meeting-report.pdf?ua=1 [128]
- Measles Verification Q&A. http://www.wpro.who.int/mediacentre/releases/2015/final_rvc_measlesverificationqa.pdf [129]
- Final report: Plan of Action for Maintaining Measles, Rubella, and Congenital Rubella Syndrome Elimination in the Region of the Americas <http://bit.ly/2cx8jAP> [130]
- Measles elimination in the Americas. http://www.paho.org/hq/index.php?option=com_content&view=article&id=12526%3Ameasles-elimination-in-the-americas&catid=6648%3Afact-sheets&Itemid=40721&lang=en [131]

- Immunization, Vaccines and Biologicals, Measles and Rubella Surveillance Data. https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_monthlydata/en/ [132]
- WHO-UNICEF estimates of MCV2 coverage. Methods, materials and process. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragemcv2.html [121]
- WHO vaccine-preventable diseases: monitoring system. 2019 global summary. http://apps.who.int/immunization_monitoring/globalsummary [133]
- Measles in the two european region. http://www.euro.who.int/__data/assets/pdf_file/0006/407346/Measles-Situation-report-July-2019_final-2.pdf?ua=1 [134]
- Conclusions of the 8th meeting of the European Regional Verification Commission for Measles and Rubella Elimination, held 12-14 June 2019. http://www.euro.who.int/__data/assets/pdf_file/0009/410967/8th-RVC-report-annex.pdf?ua=1 [135]
- Epidemiological Update Measles 18 June 2019. https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=measles-2204&alias=49076-18-june-2019-measles-epidemiological-update-1&Itemid=270&lang=en [136]
- Epidemiological Update Measles 7 August 2019. https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=measles-2204&alias=49586-7-august-2019-measles-epidemiological-update-1&Itemid=270&lang=en [137]
- Epidemiological Update Measles 13 December 2019. https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=measles-2204&alias=51238-13-december-2019-measles-epidemiological-update-1&Itemid=270&lang=en [138]

Documents des Centers for Disease Control des États-Unis :

- Progress towards measles elimination—Worldwide, 2000 to 2014. <http://www.cdc.gov/mmwr/pdf/wk/mm6444.pdf> [139]
- Measles Reemergence in Ceará, Northeast Brazil, 15 years after Elimination, Leite R.D. et coll. Emerging Infectious Diseases, septembre 2015. <https://wwwnc.cdc.gov/eid/article/21/9/pdfs/15-0391.pdf> [140]

Schistosomiase

- Allen AM et al. Schistosomes in Vietnam, Letter, Lancet June 1974; 1(7867) : 1175-1176.
- Chitsulo L et al. The global status of schistosomiasis and its control. Act Trop 2000; 77 : 41-51.
- CDC. Yellow Book. 2005-2006.
- Duong TH et al. La bilharziose à S. Mekongi le long du Mekong et de ses affluents Mun et Tonle Sap. Méd tropicale 1987; 47(4) : 321-328.
- Hardalo C. Schistosomiasis in travelers. Travel Medicine Advisor Update, juillet août 1996.
- Larivière M. Epidemiology of human bilharziasis. Revue du praticien 1993; 43 (4) : 417-23.
- World Health Organization. Atlas of the global distribution of schistosomiasis. Genève. World Health Organization, 1987.
- World Health Organization. Report of the WHO informal consultation on schistosomiasis control. Genève, World Health Organization, 1998.
- World Health Organization. Report of the WHO informal consultation on schistosomiasis in low transmission areas : control strategies and criteria for elimination. Genève, World Health Organization, 2000.

Thyphoïde

Nouvelles références pour l'édition 2015 :

- Déclaration concernant les voyageurs internationaux et la thyphoïde, Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV), 2014, http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-98-2014-fra.pdf [141]
- Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroentero 2007 Sept;102(9):2047-56

Références des éditions antérieures :

- CCMTMV. Déclaration concernant la fièvre thyphoïde et les voyages à l'étranger. RMTC 1994;20-8 : 61-68.
- CDC. Typhoid immunization : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1994;43(RR-14) : 1-7.
- Comité consultatif national de l'immunisation (CCNI). Déclaration sur l'immunisation contre la thyphoïde. Santé et Bien-Être social Canada. RMTC 1993;19(2).
- Connor BA, Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 2005;5 : 623-628.
- Crum NF. Current trends in typhoid fever. Curr Gastroenterol Rep 2003;5 : 279-286.
- Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004;82 : 346-353.
- Crump JA, Youssef FG, Luby SP et al. Estimating the incidence of typhoid fever and other febrile illnesses in developing countries. Emerg Infect Dis 2003;9 : 539-544.
- Engels EA, Falagas ME, Lau J et al. Typhoid vaccines : a meta-analysis of studies on efficacy and toxicity. BMJ 1998;316.110-116.
- Jelinek T et al. Risk factors for typhoid fever in travelers. J Travel Med 1996; 3(4) : 200-203.
- Katherine J. Johnson, From the CDC: New Country-Specific Recommendations for Pre-Travel Typhoid

Vaccination, Journal of Travel Medicine 2011; Volume 18 (Issue 6): 430-433

- Keitel Wendy et al. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 1994; 12(3) : 195-199.
- Klugman KP et al. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14 (5) : 435-438.
- Kollaritsch, Herwig et al. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Inf Dis 1997; 175 : 871-5.
- Levine MM et al. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. JAMA February 27 1991; 265(8) : 970.
- Mathieu J et al. Typhoid fever in New York City 1980 through 1990. Arch Internal Med 1994; 154(15) : 1713-1721.
- Mermin JH, Townes JM, Gerber M et al. Typhoid fever in the United States, 1985-1994. Arch Intern Med 1998;158 : 633-638.
- Papadimitropoulos V, Vergidis PI, Bliziotis I et al. Vaccination against typhoid fever in travellers: a cost-effectiveness approach. Clin Microbiol Infect 2004;10 : 681-683.
- Parry CM, Hien TT, Dougan G et al. Typhoid fever. N Engl J Med 2002;347 : 1770-1782.
- Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the Vicapsular polysaccharide. Arch Intern Med 1995; 155 : 2293-2299.
- Santé Canada. Relevé des maladies transmissibles au Canada 30 novembre 1995; 21(22) : 197-204.
- Steinberg EB, Bishop R, Haber P et al. Typhoid fever in travelers : who should be targeted for prevention? Clin Infect Dis 2004;39 : 186-191.
- Tacket CO, Levine MM et al. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine August 1988; 6 : 307-308.
- Trépanier, S.; Blackburn, M.; Milord, F. (2010) Description de l'incidence et de certains facteurs de risque de la malaria, l'hépatite A, la typhoïde et la shigellose chez les voyageurs québécois. Bibliothèque du Québec et du Canada.
- Typhoid immunization. Recommendations and reports. Morbidity and mortality weekly report December 9 1994; 43 (RR-14).
- Viret JF, Cryz SJ Jr. Protective immunity by typhoid fever and vaccination. Vaccine 1995; 26 (Suppl 2) : 150-159.
- Woodruff BA. A new look at typhoid vaccination : information for the practicing physician. JAMA February 13, 1991; 265 : 75-759.

Trypanosomiase africaine

- Gouvernement du Canada. <http://voyage.gc.ca/voyager/sante-securite/maladies/trypanosomiase> [142] (modifié le 28 janvier 2014).
- Organisation mondiale de la santé. <http://www.who.int/mediacentre/factsheets/fs259/fr/> [143] (édition juin 2013).

Tuberculose

- Organisation mondiale de la Santé. WHO global lists of high burden countries for tuberculosis (TB), TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB), 2021-2025. Background document. https://cdn.who.int/media/docs/default-source/hq-tuberculosis/who_globalhbcliststb_2021-2025_backgrounddocument.pdf?sfvrsn=f6b854c2_9 [144]
- Organisation mondiale de la Santé. Global Tuberculosis Report 2021. <https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021> [145]

Zika

- Institut national de santé publique du Québec. *Virus Zika* <https://www.inspq.qc.ca/zoonoses/zika> [146] (mis à jour 9 janvier 2017)
- Gouvernement du Canada. *Pour les professionnels de la santé: Virus Zika*. <http://canadiensensante.gc.ca/diseases-conditions-maladies-affections/disease-maladie/zika-virus/> [147]professionals-professionnels-fra.php?id=health_prof (modifié le 2 septembre 2016)
- World Health Organization. *Zika virus Fact Sheet*. <http://www.who.int/mediacentre/factsheets/zika/en/> [148] (Mis à jour le 6 septembre 2016)
- Centers for Disease Control and Prevention. *Yellow book 2016* <https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/zika> [149]
- Centers for Disease Control and Prevention. *Guillain-Barré syndrom and Flu vaccine (GBS)? Questions and answers* <http://www.cdc.gov/flu/protect/vaccine/guillainbarre.htm> [150] (Mis à jour le 16 octobre 2015)
- World Health Organization. *Guillain-Barré syndrome Fact Sheet* <http://www.who.int/mediacentre/factsheets/guillain-barre-syndrome/en/> [151]
- Ministère de la santé et des Services sociaux. *Recommandations pour les professionnels de la santé: Prévention et dépistage de l'infection par le virus Zika chez la femme enceinte ou désirant le devenir et son partenaire (Version 3)* http://www.msss.gouv.qc.ca/professionnels/documents/zika/zika_chu.pdf [152] (Mise à jour du 23 août 2016)
- World Health Organization. *Infant feeding in areas of Zika virus transmission- Summary of Rapid advice Guidelines* http://apps.who.int/iris/bitstream/10665/204473/1/WHO_ZIKV_MOC_16.5_eng.pdf?ua=1 [153] (29 juin 2016)
- Centers for Disease Control and Prevention. *All Countries & Territories with Active Zika Virus Transmission* <https://www.cdc.gov/zika/geo/active-countries.html> [154]
- World Health Organization. *Situation report - Zika virus, Microcephaly, Guillain-Barré syndrome -24 november 2016* <http://apps.who.int/iris/bitstream/10665/251648/1/zikasitrep24Nov16-eng.pdf?ua=1> [155]
- Institut national de santé publique du Québec *Bulletin de vigie en santé des voyageurs - Mise à jour sur le virus Zika* <https://www.inspq.qc.ca/surveillance-des-actualites-en-sante-des-voyageurs/v17-n7> [156]
- The Florida Department of Health <http://www.floridahealth.gov/newsroom/all-articles.html> [157]
- Institut national de santé publique du Québec. *Guide d'intervention santé-voyage - Risques à la santé- Dengue* <https://www.inspq.qc.ca/sante-voyage/guide/risques/dengue/prevention> [158]

- Gouvernement du Canada - *Prévention du virus Zika*
<http://canadiensensante.gc.ca/diseases-conditions-maladies-affections/disease-maladie/zika-virus/prevention-fra.php> [159]
- Gouvernement du Québec - *Portail Santé-Mieux-être - Virus Zika*
<http://www.sante.gouv.qc.ca/chroniques/virus-zika/> [160]
- Organisation Mondiale de la Santé - *Virus Zika: information pour les voyageurs se rendant dans les pays affectés* <http://www.who.int/csr/disease/zika/information-for-travelers/fr/> [161] (Mis à jour 6 septembre 2016)

Institut national de santé publique **Québec**



© Gouvernement du Québec, 2022

URL source (modified on 12/29/2021 - 18:05): <https://www.inspq.qc.ca/sante-voyage/guide/references>

Liens

- [1] http://www.phac-aspc.qc.ca/tmp-pmv/pub_f.html
- [2] <http://www.cdc.gov/travel/index.htm>
- [3] <http://www.odci.gov/cia/publications/factbook/index.html>
- [4] <http://www.iamat.org>
- [5] <http://www.dfait-maeci.gc.ca/geo/menu-f.asp>
- [6] <http://www.who.int/fr/index.html>
- [7] <http://www.paho.org/english/country.htm>
- [8] http://www.phac-aspc.gc.ca/tmp-pmv/236_f.html
- [9] <http://travel.state.gov/travel/tips/health/health-1185.html>
- [10] <http://www.worldbank.org/html/extdr/regions.htm>
- [11] <http://www.paho.org>
- [12] <http://idsc.nih.gov/iasr/iasr-ge1.html>
- [13] <http://www.who.int/csr/don/archive/disease/cholera/en>
- [14] <http://www.who.int/ith/en/>
- [15] <http://www.who.int/gho>
- [16] <http://www.paho.org/cholera>
- [17] http://www.paho.org/hq/index.php?option=com_topics&view=article&id=13&Itemid=40745&lang=en
- [18] <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc>
- [19] <http://www.who.int/wer>
- [20] <http://www.professionsante.ca/>
- [21] <http://www.cdc.gov/eid>
- [22] <http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm>

[23] <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics>

[24] <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm>

[25] <https://hpr-rps.hres.ca/reg-content/resume-examen-innocuite-detail.php?lang=fr&linkID=SSR00226#footnotes>

[26] <http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/fluoroquinolones2-fra.php>

[27] <http://wwwnc.cdc.gov/travel/yellowbook/2016/the-pre-travel-consultation/travelers-diarrhea>

[28] <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/05vol31/asc-dcc-7/index-fra.php>

[29] <http://www.voyage.gc.ca/voyager/sante-securite/rehydratation>

[30] <http://infection.thelancet.com>

[31] <http://www.wolterskluwercdi.com/lexicomp-online/>

[32] <http://publications.msss.gouv.qc.ca/msss/fichiers/piq/chap10-6-1.pdf>

[33] <http://www.collectionscanada.gc.ca/webarchives/20071124190633/http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/01pdf/acs27-3.pdf>

[34] <http://webedition.sanfordguide.com/>

[35] <http://www.who.int/fr/news-room/fact-sheets/detail/japanese-encephalitis>

[36] <http://www.who.int/ith/ITH-Chapter6.pdf?ua=1>

[37] <https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/japanese-encephalitis>

[38] <http://www.msss.gouv.qc.ca/professionnels/vaccination/protocole-d-immunisation-du-quebec-piq/>

[39] <http://www.promedmail.org/post/5455667>

[40] <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5402a1.htm>

[41] <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm>

[42] <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5707a1.htm>

[43] <http://publications.msss.gouv.qc.ca/msss/document-000582/>

[44] <http://stacks.cdc.gov/view/cdc/20711>

[45] <https://aidsinfo.nih.gov/>

[46] <http://www.guidetherapeutiquevih.com/feuilles-antiretroviraux.asp>

[47] <http://www.hiv-druginteractions.org/>

[48] <http://www.who.int/ith/YFrisk.pdf>

[49] <http://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm>

[50] <http://www.who.int/ith/2017-ith-country-list.pdf?ua=1>

[51] <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-11/pdf/yf-fj.pdf>

[52] <http://www.who.int/ith/en>

[53] <http://www.funasa.gov.br/pub/pub00.htm>

[54] <http://www.who.int/ith/countries/en/>

[55] <http://www.who.int/ith/updates/20160725/en/>

[56] <http://www.who.int/ith/fr/index.html>

[57] <http://www.cdc.gov/mmwr/pdf/rr/rr5907.pdf>

[58] <http://www.eurosurveillance.org/ew/2005/051201.asp#2>

[59] <http://www.phac-aspc.gc.ca/tmp-pmv/meningitis-fra.php>

[60] <http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/meningococcal-disease.htm>

[61] <http://www.who.int/emc>

[62] http://www.who.int/emc/outbreak_news/diseases_indices/men_index.html

[63] http://www.who.int/immunization/newsroom/press/news_release_3_nov_2015_meningitis_a/en/

[64] <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/15vol41/dr-rm41-05/com-2-fra.php>

[65] http://www.phac-aspc.gc.ca/tmp-pmv/info/meningitis_f.html

[66] <http://www.tripprep.com/scripts/main/default.asp>

[67] <http://www.who.int/emc/diseases/meningitis/meningart.pdf>

[68] <http://www.who.int/wer/2015/wer9047.pdf>

[69] <http://www.who.int/wer/2015/wer9013.pdf>

[70] http://apps.who.int/iris/bitstream/10665/170250/1/9789240694439_eng.pdf?ua=1&ua=1

[71] http://www.phac-aspc.gc.ca/fluwatch/index_f.html

[72] http://www.hc-sc.gc.ca/pphb-dgspsp/tmp-pmv/2000/cruzpr_f.html

[73] http://www.phac-aspc.gc.ca/tmp-pmv/2005/h5n1050203_f.html

[74] <http://www.who.int/leishmaniasis/resources/en/>

[75] <https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/leishmaniasis-visceral>

[76] <https://voyage.gc.ca/voyager/sante-securite/maladies/leishmaniose>

[77] <http://www.idsociety.org/Organism/#Leishmaniasis>

[78] <http://www.cdc.gov/ncidod/diseases/lyme/lyme.htm>

[79] <http://www.cdc.gov/ncidod/dvbid/lymeinfo.htm>

[80] http://www.phac-aspc.gc.ca/tmp-pmv/malaria_catmat-paludisme_ccmtmv-eng.php

[81] <http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/yellow-fever-malaria-information-by-country#select-seldyfm707>

[82] <http://www.who.int/ith/2016-ith-county-list.pdf?ua=1>

[83] <http://www.who.int/malaria/publications/world-malaria-report-2015/wmr2015-profiles.pdf?ua=1>

[84] <http://www.publications.gc.ca/pub?id=463471&sl=1>

[85] http://www.who.int/ith/chapters/ITH_chapter_7fr.pdf?ua=1

[86] <http://www.who.int/ith/chapters/ithcountrylistFR.pdf?ua=1>

[87] http://www.who.int/malaria/publications/world_malaria_report_2014/en/

[88] <http://www.nc.cdc.gov/travel/page/yellowbook-home-2014>

[89] <http://www.fitfortravel.nhs.uk/home.aspx>

[90] <http://www.pasteur.fr/fr/map>

[91] http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/337761/Guidelines_for_malaria_prevention_in_travellers_UK_PC.pdf

[92] <http://www.eurosurveillance.org/>

[93] <http://www.promedmail.org/>

[94] <http://www.oge.sld.pe/Asis/sala/semana/malaria.pdf>

[95] http://www.hc-sc.gc.ca/francais/virus_nil/insectifuge.html

[96] <http://www.polioeradication.org>

[97] <http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx>

[98] <http://www.moh.gov.sa/en/HealthAwareness/Hajj/Pages/005.aspx>

[99] <http://www.who.int/csr/don/archive/disease/poliomyelitis/en/>

[100] <http://www.polioeradication.org/features/countryprofiles/countries.asp#B>

[101] <http://wwwnc.cdc.gov/travel/page/yellowbook-home>

[102] <http://publications.msss.gouv.qc.ca/acrobat/f/documentation/piq/html/web/Piq.htm>

[103] <http://www.who.int/ith/fr/>

[104] <http://www.oie.int/fr/>

[105] <http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/rabies.htm>

[106] <http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/rabies>

[107] <http://healthmap.org/fr>

[108] <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/02vol28/28sup/dcc4.html>

[109] <http://www.who-rabies-bulletin.org>

[110] http://publications.msss.gouv.qc.ca/acrobat/f/documentation/piq/chap10-7_rage.pdf

[111] <http://www.who.int/mediacentre/factsheets/fs099/en>

[112] <http://www.who.int/rabies/en>

[113] <http://www.who.int/rabies/epidemiology/Rabiessurveillance.pdf>

[114] <http://www.who.int/wer/2010/wer8532.pdf>

[115] http://www.oie.int/wahis/public.php?page=disease_status_detail

[116] <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/15vol41/dr-rm41-07/ar-01-fra.php>

[117] http://www.msss.gouv.qc.ca/professionnels/documents/rougeole/etat_situation.pdf

[118] http://publications.msss.gouv.qc.ca/msss/fichiers/flashvigie/06-271-02W-vol10_no2.pdf

[119] <http://www.who.int/mediacentre/factsheets/fs286/fr/>

[120] <http://www.who.int/ith/vaccines/measles/en/>

[121] http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragemcv2.html

[122] http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles/en/

[123] http://www.who.int/immunization/monitoring_surveillance/data/ga_amrprofile.pdf?ua=1

[124] http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gid=29016&lang=en

[125] http://www.paho.org/hq/index.php?option=com_topics&view=rdmore&cid=8321&Itemid=40899&lang=en

[126] <http://www.euro.who.int/en/health-topics/communicable-diseases/measles-and-rubella>

[127] http://www.euro.who.int/__data/assets/pdf_file/0009/247356/Eliminating-measles-and-rubella-Framework-for-the-verification-process-in-the-WHO-European-Region.pdf?ua=1

[128] http://www.euro.who.int/__data/assets/pdf_file/0011/304958/4th-RVC-meeting-report.pdf?ua=1

[129] http://www.wpro.who.int/mediacentre/releases/2015/final_rvc_measlesverificationqa.pdf

[130] <http://bit.ly/2cx8jAP>

[131] http://www.paho.org/hq/index.php?option=com_content&view=article&id=12526%3Ameasles-elimination-in-the-americas&catid=6648%3Afact-sheets&Itemid=40721&lang=en

[132] https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_monthlydata/en/

[133] http://apps.who.int/immunization_monitoring/globalsummary

[134] http://www.euro.who.int/__data/assets/pdf_file/0006/407346/Measles-Situation-report-July-2019_final-2.pdf?ua=1

[135] http://www.euro.who.int/__data/assets/pdf_file/0009/410967/8th-RVC-report-annex.pdf?ua=1

[136] https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=measles-2204&alias=49076-18-june-2019-measles-epidemiological-update-1&Itemid=270&lang=en

[137] https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=measles-2204&alias=49586-7-august-2019-measles-epidemiological-update-1&Itemid=270&lang=en

[138] https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=measles-2204&alias=51238-13-december-2019-measles-epidemiological-update-1&Itemid=270&lang=en

[139] <http://www.cdc.gov/mmwr/pdf/wk/mm6444.pdf>

[140] <https://wwwnc.cdc.gov/eid/article/21/9/pdfs/15-0391.pdf>

[141] http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-98-2014-fra.pdf

[142] <http://voyage.gc.ca/voyager/sante-securite/maladies/trypanosomiase>

[143] <http://www.who.int/mediacentre/factsheets/fs259/fr/>

[144] https://cdn.who.int/media/docs/default-source/hq-tuberculosis/who_globalhbcliststb_2021-2025_backgrounddocument.pdf?sfvrsn=f6b854c2_9

[145] <https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021>

[146] <https://www.inspq.qc.ca/zoonoses/zika>

[147] http://canadienssante.gc.ca/diseases-conditions-maladies-affections/disease-maladie/zika-virus/professionnels-professionnels-fra.php?id=health_prof

[148] <http://www.who.int/mediacentre/factsheets/zika/en/>

[149] <https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/zika>

[150] <http://www.cdc.gov/flu/protect/vaccine/guillainbarre.htm>

[151] <http://www.who.int/mediacentre/factsheets/guillain-barre-syndrome/en/>

[152] http://www.msss.gouv.qc.ca/professionnels/documents/zika/zika_chu.pdf

[153] http://apps.who.int/iris/bitstream/10665/204473/1/WHO_ZIKV_MOC_16.5_eng.pdf?ua=1

[154] <https://www.cdc.gov/zika/geo/active-countries.html>

[155] <http://apps.who.int/iris/bitstream/10665/251648/1/zikasitrep24Nov16-eng.pdf?ua=1>

[156] <https://www.inspq.qc.ca/surveillance-des-actualites-en-sante-des-voyageurs/v17-n7>

[157] <http://www.floridahealth.gov/newsroom/all-articles.html>

[158] <https://www.inspq.qc.ca/sante-voyage/guide/risques/dengue/prevention>

[159] <http://canadienssante.gc.ca/diseases-conditions-maladies-affections/disease-maladie/zika-virus/prevention-fra.php>

[160] <http://www.sante.gouv.qc.ca/chroniques/virus-zika/>

[161] <http://www.who.int/csr/disease/zika/information-for-travelers/fr/>